

FORM PTO-1390  
REV. 2/01T

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

05394.0013

U.S. APPLICATION NO.  
(If known, see 37CFR1.5)**09/936523**

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/FR00/00637

March 16, 2000

March 16, 1999

**TITLE OF INVENTION**

DELETED SEQUENCES IN M. BOVIS BCG/M. BOVIS OR M. TUBERCULOSIS, METHOD FOR DETECTING MYCOBACTERIA USING THESE SEQUENCES AND VACCINES

**APPLICANT(S) FOR DO/EO/US**


Stewart COLE, Stéphane GORDON, Roland BUCHRIESER-BROSCH, Alain BILLAULT, and Thierry GARNIER

Applicant(s) herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☐ A copy of the International Application as filed (35 U.S.C. 371 (c)(2)).
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed with the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).
  - a. ☒ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154 (d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)).
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

**Items 11 to 20 below concern document(s) or information included:**

11. ☐ Information Disclosure Statement under 37 CFR 1.97 and 1.98
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A Substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154 (d)(4).
19. ☐ A second copy of the English language translation of the international application 35 U.S.C. 154 (d)(4).
20. ☒ Other items or information:
  - a. ☒ Copy of cover page of International Publication No. WO 00/55362
  - b. ☒ Copy of Verification of Translation.
  - c. ☒ Copy of Sequence Listing consisting of 9 pages

U.S. APPLICATION NO. (If known, see 37CFR 1.5) <b>09/936523</b>		INTERNATIONAL APPLICATION NO. PCT/FR00/00637		ATTORNEY'S DOCKET NUMBER 05394.0013	
21. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
<b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b>					
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO .....				\$1000.00	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....				\$860.00	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search fee (37 CFR 1.445(a)(2)) paid to USPTO .....				\$710.00	
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....				\$690.00	
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33 (1)-(4) .....				\$100.00	
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	29	- 20 =	9	x \$18.00	\$162.00
Independent Claims	2	- 3 =		x \$80.00	\$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+\$270.00	\$270.00
<b>TOTAL OF THE ABOVE CALCULATIONS =</b>				\$1292.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
<b>SUBTOTAL =</b>				\$1292.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest priority date (37 CFR 1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$	
<b>TOTAL NATIONAL FEE =</b>				1292.00	
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.				+\$40.00	
<b>TOTAL FEES ENCLOSED =</b>				\$1332.00	
				Amount to be refunded:	\$
				charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1332.00</u> to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>06-0916</u> . A duplicate copy of this sheet is enclosed.					
d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.					
<b>SEND ALL CORRESPONDENCE TO:</b>					
Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. 1300 I Street, N.W. Washington, D.C. 20005-3315					
DATED: September 14, 2001				 SIGNATURE Ernest F. Chapman Reg. No. 25,961 NAME/REGISTRATION NO.	

FORM 150-1 (2-99)

164

A circular ink stamp from the Intellectual Property Office (IPO). The text "O I P E J C 152" is curved along the top inner edge. The date "NOV 20 2001" is stamped in the center. The text "PATENT &amp; TRADEMARK OFFICE" is curved along the bottom inner edge.

PATENT  
Customer No. 22,852  
Attorney Docket No. 05394-0013-00000

**In re Application of:**

Stewart COLE et al.

Group Art Unit: Not yet assigned

Serial No.: 09/936,523

Examiner: Not yet assigned

Filed: September 14, 2001

For: DELETED SEQUENCES IN M.  
BOVIS BCG/M.BOVIS OR M.  
TUBERCULOSIS, METHOD FOR  
DETECTING MYCOBACTERIA  
USING THESE SEQUENCES AND  
VACCINES

Commissioner of Patents and Trademarks  
Washington, DC 20231

Sir:

## PRELIMINARY AMENDMENT

Prior to the examination of the above application, please amend this application as follows:

### IN THE CLAIMS:

Please cancel claims 7 and 24.

Please amend the following claims:

1. (Amended) A nucleotide or polynucleotide sequence deleted from the genome of *M. bovis* BCG/*M. bovis* and present in the genome of *M. tuberculosis* or a nucleotide or polynucleotide sequence of the following ORFs and genes: Rv2346c, Rv2347c, Rv2348c, *plcC*, *plcB*, *plcA*, Rv2352c, Rv2353c, Rv3425, Rv3426, Rv3427c, Rv3428c,

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

Rv1964, Rv1965, *mce3*, Rv1967, Rv1968, Rv1969, *lprM*, Rv1971, Rv1972, Rv1973, Rv1974, Rv1975, Rv1976c, Rv1977, *ephA*, Rv3618, Rv3619c, Rv3620c, Rv3621c, Rv3622c, *IPqG*, *cobL*, Rv2073c, Rv2074, Rv2075, *echA1*, Rv0223c, RvD1-ORF1, RvD1-ORF2, Rv2024c, *plcD*, RvD2-ORF1, RvD2-ORF2, RvD2-ORF3, or Rv1758.

2. (Amended) The nucleotide or polynucleotide sequences as claimed in claim 1 grouped together in nucleotide regions RD5 to RD10 and RvD1 and RvD2 according to the following distribution:

(A) RD5: Rv2346c, Rv2347c, Rv2348c, *plcC*, *plcB*, *plcA*, Rv2352c, Rv2353c;

(B) RD6: Rv3425, Rv3426, Rv3427c, Rv3428c;

(C) RD7: Rv1964, Rv1965, *mce3*, Rv1967, Rv1968, Rv1969, *lprM*, Rv1971, Rv1972, Rv1973, Rv1974, Rv1975, Rv1976c, Rv1977;

(D) RD8: *ephA*, Rv3618, Rv3619c, Rv3620c, Rv3621c, Rv3622c, *lpqG*;

(E) RD9: *cobL*, Rv2073c, Rv2074, Rv2075c;

(F) RD10: *echA1*, Rv0223c;

(G) RvD1: RvD1-ORF1, RvD1-ORF2, Rv2024c; and

(H) RvD2: *plcD*, RvD2-ORF1, RvD2-ORF2, RvD2-ORF3, Rv1758.

3. (Amended) A method for the discriminatory detection and identification of *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample, comprising:

0936523



- (A) isolating the DNA from the biological sample to be analyzed or production of a cDNA from the RNA of the biological sample;
- (B) detecting the DNA sequences of the mycobacterium present in said biological sample; and
- (C) analyzing said sequences with the nucleotide and polynucleotide sequences as claimed in claim 1.

4. (Amended) The method as claimed in claim 3, wherein the detection of the mycobacterial DNA sequences is carried out using nucleotide sequences complementary to said DNA sequences.

5. (Amended) The method as claimed in claim 3, wherein the detection of the mycobacterial DNA sequences is carried out by amplifying the sequences using primers.

6. (Amended) The method as claimed in claim 5, wherein the primers have a nucleotide sequence chosen from the group comprising SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, and SEQ ID No. 18 wherein:

(A) the pair SEQ ID No. 1/SEQ ID No. 2 is specific for RD4;

(B) the pair SEQ ID No. 3/SEQ ID No. 4 is specific for RD5;

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

- (C) the pair SEQ ID No. 5/SEQ ID No. 6 is specific for RD6;
- (D) the pair SEQ ID No. 7/SEQ ID No. 8 is specific for RD7;
- (E) the pair SEQ ID No. 9/SEQ ID No. 10 is specific for RD8;
- (F) the pair SEQ ID No. 11/SEQ ID No. 12 is specific for RD9;
- (G) the pair SEQ ID No. 13/SEQ ID No. 14 is specific for RD10;
- (H) the pair SEQ ID No. 15/SEQ ID No. 16 is specific for RvD1; and
- (I) the pair SEQ ID No. 17/SEQ ID No. 18 is specific for RvD2.

8. (Amended) A method for the discriminatory detection and identification of *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample, comprising:

- (A) bringing the biological sample to be analyzed into contact with at least one pair of primers as defined in claim 6, the DNA contained in the sample having been, where appropriate, made accessible to the hybridization beforehand;
- (B) amplifying the DNA of the mycobacterium; and
- (C) visualizing the amplification of the DNA fragments.

9. (Amended) A kit for the discriminatory detection and identification of *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample comprising:

- (A) at least one pair of primers as defined in claim 6;

- (B) reagents necessary to carry out a DNA amplification reaction; and
- (C) optionally, the necessary components, which make it possible to verify or compare the sequence, the size of the amplified fragment, or both the sequence and the size of the amplified fragment.
10. (Amended) A method of amplifying a DNA sequence from *M. bovis* BCG/*M. bovis* or *M. tuberculosis* comprising hybridizing at least one of the pair of primers of claim 6 to the DNA sequence.
11. (Amended) A product of expression of all or part of a nucleotide or polynucleotide sequence deleted from the genome of *M. bovis* BCG/*M. bovis* and present in *M. tuberculosis* or a product of expression of all or a part of an ORF or gene of claim 1.
12. (Amended) A method for the discriminatory detection *in vitro* of antibodies directed against *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample, comprising:
- (A) bringing the biological sample into contact with at least one product as defined in claim 11, and
- (B) detecting the antigen-antibody complex formed.
13. (Amended) A method for the discriminatory detection of a vaccination with *M. bovis* BCG or an infection by *M. tuberculosis* in a mammal, comprising:
- (A) preparing a biological sample containing cells,

(B) incubating the biological sample with at least one product as defined in claim 11,  
and

(C) detecting a cellular reaction indicating prior sensitization of the mammal to said  
product, wherein the cellular reaction is cell proliferation, synthesis of proteins, or both  
cell proliferation and synthesis of proteins such as gamma interferon.

14. (Amended) A kit for the *in vitro* diagnosis of an *M. tuberculosis* infection in a  
mammal optionally vaccinated beforehand with *M. bovis* BCG comprising:

(A) a product as defined in claim 11;

(B) where appropriate, reagents for the constitution of the medium suitable for the  
immunological reaction;

(C) reagents allowing the detection of the antigen-antibody complexes produced by  
the immunological reaction;

(D) where appropriate, a reference biological sample (negative control) free of  
antibodies recognized by said product; and

(E) where appropriate, a reference biological sample (positive control) containing a  
predetermined quantity of antibodies recognized by said product.

15. (Amended) A mono- or polyclonal antibody, or its chimeric fragments or  
antibodies, wherein the antibodies or fragments are capable of specifically recognizing a  
product as defined in claim 11.

0936523-0013

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

16. (Amended) A method for the discriminatory detection of the presence of an antigen of *M. bovis* BCG/ *M. bovis* or *M. tuberculosis* in a biological sample comprising:

(A) bringing the biological sample into contact with an antibody as claimed in claim 15; and

(B) detecting the antigen-antibody complex formed.

17. (Amended) A kit for the discriminatory detection of the presence of an antigen of *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample comprising:

(A) an antibody as claimed in claim 15;

(B) reagents for constituting the medium suitable for the immunological reaction; and

(C) reagents allowing the detection of the antigen-antibody complexes produced by the immunological reaction.

18. (Amended) An immunological composition, comprising at least one product as defined in claim 11, and a pharmaceutically compatible vehicle.

19. (Amended) The vaccine of claim 18, further comprising one or more immunity adjuvants.

20. (Amended) A method for the discriminatory detection and identification of *M. bovis* BCG or *M. tuberculosis* in a biological sample comprising the following steps:

09/936,523

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

(A) digesting with *HindIII*, of at least part of the genome of the mycobacterium present in a biological sample to be analyzed; and

(B) analyzing restriction fragments thus obtained.

21. (Amended) The method as claimed in claim 20, wherein the analysis of the restriction fragments comprises counting said fragments, determining the length of said fragments, or both counting said fragments and determining the length of said fragments.

22. (Amended) The method of detection as claimed in claim 20, wherein the analysis of the restriction fragments comprises bringing the fragments into contact with at least one probe under stringent hybridization conditions and identifying the fragments hybridized.

23. (Amended) The method as claimed in claim 22, wherein the probe is obtained by amplification of the genomic DNA with primers chosen from the group SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 33, or SEQ ID No. 34 with the pair:

(A) SEQ ID No. 31/SEQ ID No. 32 specific for DU1; or

(B) SEQ ID No. 33/SEQ ID No. 34 specific for DU2.

25. (Amended) The method as claimed in claim 20, wherein the analysis of the fragments obtained comprises amplification with primers and sequencing, wherein the primers are chosen from the group SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, SEQ

0936523-0013-00000

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

ID No. 27, SEQ ID No. 28, SEQ ID No. 35, SEQ ID No. 36, SEQ ID No. 37, and SEQ ID No. 38, wherein

(A) SEQ ID No. 19, SEQ ID No. 20/SEQ ID No. 21 are specific for JDU1;

(B) SEQ ID No. 22, SEQ ID No. 24/SEQ ID No. 23, SEQ ID No. 25 are specific for JDU2A;

(C) SEQ ID No. 26/SEQ ID No. 27, SEQ ID No. 28 are specific for JDU2B

(D) SEQ ID No. 36, SEQ ID NO. 37, SEQ ID No. 38 are specific for DU1.

Please add the following new claims:

25. (NEW) The method of claim 13, wherein the biological sample containing cells is a sample of cells of the immune system.

26. (NEW) The method of claim 25, wherein the cells of the immune system are T cells.

27. (NEW) The method of claim 13, wherein the cellular reaction detected is synthesis of gamma-interferon.

#### **REMARKS**

Entry of this Amendment prior to examination is respectfully requested. The amendments to the claims were made to conform with United States patent practice.

They do not add new matter to the claims.

The amendment of Claims 21 and 22 changes the description of analysis methods from "consists" to "comprises." Support for these changes can be found, for example, on page 20 of the specification. Here, methods of analysis are described in terms that contemplate the methods delineated in the claims, as well as other methods. Specifically, the specification reads, "As regards the analysis of restriction fragments, it *may* consist in counting said fragments and/or in determining their length." (Specification page 20, lines 4-6, emphasis added.) Furthermore, the next paragraph begins with the statement, "*Another way of analyzing* the restriction fragments resulting from the enzymatic digestion of the genome of the mycobacterium as described above consists in bringing said fragments into contact with at least one appropriate probe, covering *for example* the duplicated region, under hybridization conditions so as to then identify the number and size of the fragments which have hybridized." (Specification page 20, lines 19-21, emphasis added.) These statements demonstrate that analysis of the fragments can include various techniques and methods.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: November 20, 2001

By: 

Kenneth J. Meyers  
Reg. No. 25,146

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000



**Appendix to Amendment of November 20, 2001**

Please amend the claims as follows:

1. (Amended) A [Nucleotide] nucleotide or polynucleotide [sequences] sequence deleted from the genome of *M. bovis* BCG/*M. bovis* and present in the genome of *M. tuberculosis* or [conversely chosen from] a nucleotide or polynucleotide sequence of the following ORFs and genes: Rv2346c, Rv2347c, Rv2348c, *plcC*, *plcB*, *plcA*, Rv2352c, Rv2353c, Rv3425, Rv3426, Rv3427c, Rv3428c, Rv1964, Rv1965, *mce3*, Rv1967, Rv1968, Rv1969, *lprM*, Rv1971, Rv1972, Rv1973, Rv1974, Rv1975, Rv1976c, Rv1977, *ephA*, Rv3618, Rv3619c, Rv3620c, Rv3621c, Rv3622c, *lpqG*, *cobL*, Rv2073c, Rv2074, Rv2075, *echA*, Rv0223c, RvD1-ORF1, RvD1-ORF2, Rv2024c, *plcD*, RvD2-ORF1, RvD2-ORF2, RvD2-ORF3, or Rv1758.
2. (Amended) The nucleotide or polynucleotide sequences as claimed in claim 1 grouped together in nucleotide regions RD5 to RD10 and RvD1 and RvD2 according to the following distribution:
  - [-] (A) RD5: Rv2346c, Rv2347c, Rv2348c, *plcC*, *plcB*, *plcA*, Rv2352c, Rv2353c[.];
  - [-] (B) RD6: Rv3425, Rv3426, Rv3427c, Rv3428c[.];
  - [-] (C) RD7: Rv1964, Rv1965, *mce3*, Rv1967, Rv1968, Rv1969, *lprM*, Rv1971, Rv1972, Rv1973, Rv1974, Rv1975, Rv1976c, Rv1977[.];
  - [-] (D) RD8: *ephA*, Rv3618, Rv3619c, Rv3620c, Rv3621c, Rv3622c, *lpqG*[.];

004460-000000

[-] (E) RD9: *cobL*, Rv2073c, Rv2074, Rv2075c[.];

[-] (F) RD10: *echA1*, Rv0223c[.];

[-] (G) RvD1: RvD1-ORF1, RvD1-ORF2, Rv2024c; and

[-] (H) RvD2: *plcD*, RvD2-ORF1, RvD2-ORF2, RvD2-ORF3, Rv1758.

3. (Amended) A method for the discriminatory detection and identification of *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample, comprising [the following steps]:

[a)](A) [isolation of] isolating the DNA from the biological sample to be analyzed or production of a cDNA from the RNA of the biological sample[.];

[b)](B) [detection of] detecting the DNA sequences of the mycobacterium present in said biological sample[.]; and

[c)](C) [analysis of] analyzing said sequences with the nucleotide and polynucleotide sequences as claimed in claim 1 [or 2].

4. (Amended) The method as claimed in claim 3, [in which] wherein the detection of the mycobacterial DNA sequences is carried out using nucleotide sequences complementary to said DNA sequences.

5. (Amended) The method as claimed in claim 3, [or 4, in which] wherein the detection of the mycobacterial DNA sequences is carried out by [amplification of these] amplifying the sequences using primers.

09955-0940

6. (Amended) The method as claimed in claim 5, [in which] wherein the primers have a nucleotide sequence chosen from the group comprising SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, and SEQ ID No. 18 [with] wherein:

(A) the pair SEQ ID No. 1/SEQ ID No. 2 is specific for RD4;

[-] (B) the pair SEQ ID No. 3/SEQ ID No. 4 is specific for RD5[.];

[-] (C) the pair SEQ ID No. 5/SEQ ID No. 6 is specific for RD6[.];

[-] (D) the pair SEQ ID No. 7/SEQ ID No. 8 is specific for RD7[.];

[-] (E) the pair SEQ ID No. 9/SEQ ID No. 10 is specific for RD8[.];

[-] (F) the pair SEQ ID No. 11/SEQ ID No. 12 is specific for RD9[.];

[-] (G) the pair SEQ ID No. 13/SEQ ID No. 14 is specific for RD10[.];

[-] (H) the pair SEQ ID No. 15/SEQ ID No. 16 is specific for RvD1[.]; and

[-] (I) the pair SEQ ID No. 17/SEQ ID No. 18 is specific for RvD2[.];

8. (Amended) A method for the discriminatory detection and identification of *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample, comprising [the following steps]:

09955660 " 0944T 04704

[a)](A) bringing the biological sample to be analyzed into contact with at least one pair of primers as defined in claim 6 [or 7], the DNA contained in the sample having been, where appropriate, made accessible to the hybridization beforehand[.];

[b)](B) [amplification of] amplifying the DNA of the mycobacterium[.]; and

[c)](C) [visualization of] visualizing the amplification of the DNA fragments.

9. (Amended) A kit for the discriminatory detection and identification of *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample comprising [the following elements]:

[a)](A) at least one pair of primers as defined in claim 6 [or 7.];

[b)](B) [the] reagents necessary to carry out a DNA amplification reaction[.]; and

[c)](C) optionally, the necessary components, which make it possible to verify or compare the sequence [and/or], the size of the amplified fragment, or both the sequence and the size of the amplified fragment.

10. (Amended) [The use of at least one pair of primers as defined in claim 6 or 7 for the amplification of] A method of amplifying a DNA sequence from *M. bovis* BCG/*M. bovis* or *M. tuberculosis* comprising hybridizing at least one of the pair of primers of claim 6 to the DNA sequence.

11. (Amended) A product of expression of all or part of [the] a nucleotide or polynucleotide [sequences] sequence deleted from the genome of *M. bovis* BCG/*M.*

FILED OCT 1 2009

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

*bovis* and present in *M. tuberculosis* or [conversely as defined in] a product of expression of all or a part of an ORF or gene of claim 1.

12. (Amended) A method for the discriminatory detection *in vitro* of antibodies directed against *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample, comprising [the following steps]:

[a)](A) bringing the biological sample into contact with at least one product as defined in claim 11, and

[b)](B) detecting the antigen-antibody complex formed.

13. (Amended) A method for the discriminatory detection of a vaccination with *M. bovis* BCG or an infection by *M. tuberculosis* in a mammal, comprising [the following steps]:

[a)](A) [preparation of] preparing a biological sample containing cells[, more particularly cells of the immune system of said mammal and more particularly still T cells],

[b)](B) [incubation of] incubating the biological sample [of step a)] with at least one product as defined in claim 11, and

[c)](C) [detection of] detecting a cellular reaction indicating prior sensitization of the mammal to said product, [in particular] wherein the cellular reaction is cell proliferation [and/or], synthesis of proteins [such as gamma-interferon], or both cell proliferation and synthesis of proteins such as gamma interferon.

104T60" E255E650

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

14. (Amended) A kit for the *in vitro* diagnosis of an *M. tuberculosis* infection in a mammal optionally vaccinated beforehand with *M. bovis* BCG comprising:

[a)](A) a product as defined in claim 11[.];

[b)](B) where appropriate, [the] reagents for the constitution of the medium suitable for the immunological reaction[.];

[c)](C) [the] reagents allowing the detection of the antigen-antibody complexes produced by the immunological reaction[.];

[d)](D) where appropriate, a reference biological sample (negative control) free of antibodies recognized by said product[.]; and

[e)](E) where appropriate, a reference biological sample (positive control) containing a predetermined quantity of antibodies recognized by said product.

15. (Amended) A mono- or polyclonal antibody, or its chimeric fragments or antibodies, [characterized in that they are] wherein the antibodies or fragments are capable of specifically recognizing a product as defined in claim 11.

16. (Amended) A method for the discriminatory detection of the presence of an antigen of *M. bovis* BCG/ *M. bovis* or *M. tuberculosis* in a biological sample comprising [the following steps]:

[a)](A) bringing the biological sample into contact with an antibody as claimed in claim 15[.]; and

[b)](B) detecting the antigen-antibody complex formed.

17. (Amended) A kit for the discriminatory detection of the presence of an antigen of *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample comprising [the following steps]:

[a)](A) an antibody as claimed in claim 15[.];

[b)](B) [the] reagents for constituting the medium suitable for the immunological reaction[.]; and

[c)](C) [the] reagents allowing the detection of the antigen-antibody complexes produced by the immunological reaction.

18. (Amended) An immunological composition, [characterized in that it comprises] comprising at least one product as defined in claim 11, and a pharmaceutically compatible vehicle.

19. (Amended) [A] The vaccine of claim 18, [characterized in that it comprises] further comprising [at least one product as defined in claim 11 in combination with a pharmaceutically compatible vehicle and, where appropriate,] one or more [appropriate] immunity adjuvants.

20. (Amended) A method for the discriminatory detection and identification of *M. bovis* BCG or *M. tuberculosis* in a biological sample comprising the following steps:

09/936,523

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

[-] (A) [digestion] digesting with *HindIII*, of at least part of the genome of the mycobacterium present in a biological sample to be analyzed[,] ; and

[-] (B) [analysis of the] analyzing restriction fragments thus obtained.

21. (Amended) The method as claimed in claim 20, [in which] wherein the analysis of the restriction fragments [consists in] comprises counting said fragments [and/or in],  
determining [their] the length of said fragments, or both counting said fragments and  
determining the length of said fragments.

22. (Amended) The method [Method] of detection as claimed in [either of claims]  
claim 20, [and 21, in which] wherein the analysis of the restriction fragments [consists  
in] comprises bringing [them] the fragments into contact with at least one probe under  
stringent hybridization conditions and [in] identifying the [fragment parts or fragment]  
fragments hybridized.

23. (Amended) [A] The method as claimed in claim 22, wherein [characterized in  
that] the probe is obtained by amplification of the genomic DNA with primers chosen  
from the group SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 33, or SEQ ID No. 34 with  
the pair:

[-] (A) SEQ ID No. 31/SEQ ID No. 32 specific for DU1; or

[-] (B) SEQ ID No. 33/SEQ ID No. 34 specific for DU2.

25. (Amended) The method as claimed in claim 20, [characterized in that] wherein  
the analysis of the fragments obtained comprises [are amplified] amplification with

099653-09401

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000



primers and sequencing, wherein the primers are chosen from the group SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 35, SEQ ID No. 36, SEQ ID No. 37, and SEQ ID No. 38, wherein

(A) SEQ ID No. 19, SEQ ID No. 20/SEQ ID No. 21 are specific for JDU1;

(B) SEQ ID No. 22, SEQ ID No. 24/SEQ ID No. 23, SEQ ID No. 25 are specific for JDU2A;

(C) SEQ ID No. 26/SEQ ID No. 27, SEQ ID No. 28 are specific for JDU2B

(D) SEQ ID No. 36, SEQ ID NO. 37, SEQ ID No. 38 are specific for DU1.

09/936,523

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

DELETED SEQUENCES IN *M. BOVIS* BCG/*M. BOVIS* OR *M.*  
TUBERCULOSIS, METHOD FOR DETECTING MYCOBACTERIA USING  
THESE SEQUENCES AND VACCINES

5 The subject of the present invention is the  
identification of nucleotide sequences which make it  
possible in particular to distinguish, in diagnostic  
terms, an immunization resulting from a BCG vaccination  
from an *M. tuberculosis* infection. The sequences in  
10 question are specific either to *M. bovis* BCG/*M. bovis*,  
or to *M. tuberculosis*. The subject of the present  
invention is also a method for detecting the sequences  
in question, a method for detecting antibodies  
generated by the products of expression of these  
15 sequences and the kits for carrying out these methods.  
Finally, the subject of the present invention is novel  
vaccines.

The high rate of mortality and morbidity caused by  
20 *Mycobacterium tuberculosis*, the etiological agent for  
tuberculosis, brings about the need to develop novel  
vaccines and ever shorter chemotherapeutic treatments.  
Indeed, the appearance of *M. tuberculosis* strains  
resistant to antituberculars and the increased risk in  
25 immunosuppressed patients, for example in AIDS  
patients, of developing tuberculosis, necessitates the  
development of rapid, specific and reliable methods for  
the diagnosis of tuberculosis and the development of  
novel vaccines. The conventional BCG vaccine is derived  
30 from a *Mycobacterium bovis* strain which was attenuated  
by repeated serial passages on bile potato-glycerinox  
agar (Calmette, 1927; Bloom and Fine, 1994). However,  
in spite of almost 50 years of worldwide use, the  
reason for the attenuation of *M. bovis* BCG is still  
35 unknown. Questions remain as regards the protection  
conferred by the vaccine against pulmonary  
tuberculosis, with an efficacy of between 0 and 80%  
(Fine, 1994). Furthermore, many BCG substrains exist  
and offer various levels of protection against

09936523-091401

09936523 "091401  
tuberculosis in a mouse model (Lagranderie et al., 1996). The attenuation of the original *M. bovis* strain may have been caused by mutations in the genome of the bacillus which were selected during serial passages of the strain, which mutations remained stable in the genome. However, as the original *M. bovis* strain has been lost, direct comparison between it and *M. bovis* BCG is impossible. In spite of that, the identification of genetic differences between *M. bovis*, *M. bovis* BCG and *M. tuberculosis* is likely to reveal locations whose alteration may have led to the attenuation of *M. bovis* BCG.

The *M. tuberculosis* DNA has more than 99.9% homology with the DNA of the other members of the tuberculous complex (*M. bovis*, *M. microtis*, *M. africanum*). Although closely related, these strains may be differentiated on the basis of their host range, their virulence for humans and their physiological characteristics (Heifets and Good, 1994). As in the case of the attenuation of BCG, the genetic base for the phenotypic differences between the tubercle bacilli is mainly unknown. However, the wealth of information contained in the genomic sequence of *M. tuberculosis* H37Rv led to the thought that the genetic variations between the strains was going to be revealed (Cole et al., 1998). Genomic comparison presents a powerful tool for such research studies since the whole genomes may be studied in preference to the study of genes in their individual forms. A previous comparative study of *M. bovis* and *M. bovis* BCG by subtractive genomic hybridization has shown that three regions, designated RD1, RD2 and RD3, were deleted in *M. bovis* BCG compared to *M. bovis* (Mahairas et al., 1996). However, the role, where appropriate, of these regions in the attenuation of *M. bovis* BCG has not been clearly established. Similarly, other studies of genomic differences between *M. bovis*, *M. bovis* BCG and *M. tuberculosis* have shown that many polymorphic locations existed between these strains (Philipp et al., 1996). Although the exact

nature of these polymorphisms has not been elucidated, additional analyses have revealed that a polymorphism was due to the deletion of 12.7 kb in *M. bovis* and BCG compared to *M. tuberculosis* (Brosch et al., 1998). From that, it appears that there are two classes of deletion: those which are absent from BCG but present in *M. bovis* and *M. tuberculosis* and those which are absent from *M. bovis* and BCG but present in *M. tuberculosis*.

The bacterial artificial chromosome (BAC) library for *M. tuberculosis* H37Rv deposited at the CNCM under No. I-1945 on November 19, 1997 and described in application WO9954487 demonstrates complete knowledge of the genomic sequence of *M. tuberculosis* and presents a potential as a tool for postgenomic applications such as genomic comparisons (Brosch et al., 1998). To push the investigations into the genomic differences between *M. tuberculosis* and *M. bovis* BCG even further, the inventors prepared a BAC library from *M. bovis* BCG deposited on June 30, 1998 at the CNCM under No. I-2049 and described in application WO9954487. This type of library indeed has certain advantages. Firstly, the BAC system can maintain large inserts of mycobacterial DNA, up to 120 kb. The 4.36 Mb of *M. bovis* BCG genome could therefore be represented in 50 to 60 clones, simplifying the storage and handling of the library. Secondly, the BAC system can allow, in complete confidence, replication of the inserts without generic rearrangement or deletion in the clones. From that, alterations of the insert cannot be at the origin of an error for the duration in the genome. Thirdly, the positioning of the BAC clones on the *M. bovis* BCG chromosome is likely to generate a map of clones which overlap, which ought to allow direct comparison of the local segments on the *M. tuberculosis* and *M. bovis* BCG genome, while being a resource of interest for the sequencing of the *M. bovis* BCG genome.

The construction of a BAC library for *M. bovis* BCG-Pasteur (I-2049) is described below as well as its use, in conjunction with the BAC library for *M. tuberculosis* H37Rv (I-1945), as a tool for genomic comparison. With  
5 this approach, the inventors have been able to identify novel deletions and insertions between the tubercle bacilli, which makes it possible to have a picture in two genomes of the dynamics and differentiation in the *M. tuberculosis* complex.

10

The main route for extracting biological information from the genome is the comparison between the genomes. The technology of biochips or "DNA chips" (Chee et al., 1996; DeRisi et al., 1997) described, for example, in  
15 patents No. WO97/02357 and No. WO97/29212 makes it possible to make alignments and to select the sequences of interest. However, the availability of a minimum set of BAC clones for the genomes of *M. bovis* BCG and *M. tuberculosis* H37Rv has offered the inventors ready-  
20 to-use tools for the abovementioned comparative studies. The BAC library for *M. bovis* BCG contains more than 1500 clones with an average size of inserts of about 75 kb. 57 clones cover the BCG genome including a *HindIII* fragment of 120 kb which was absent from the  
25 *M. tuberculosis* BAC library. The construction of BAC chips from the *M. bovis* BCG library should allow the inventors to extend their comparative studies relating to the tubercle bacillus. These fragments can be hybridized with the genomic DNA from clinical isolates  
30 from *M. tuberculosis* or epidemic strains in order to identify other deletions or rearrangements, and from that, allow a novel picture relating to the plasticity of the genome as well as the identification of the genes and the gene products which may be involved in  
35 the virulence.

At the end of the experiments reported here, the inventors identified 10 locations or loci which are absent from *M. bovis* BCG compared to *M. tuberculosis*.

05936523 091401

Hybridizations with the genomic DNA of *M. bovis* revealed that 7 of these loci were also deleted in *M. bovis* compared to *M. tuberculosis*. Thus, in the text below, every time reference is made to the characteristics common to the genome of *M. bovis* BCG and to that of *M. bovis* it will be indicated that this means the "genome of *M. bovis* BCG/*M. bovis*".

It was then found that 3 of the specific deletions which appeared in *M. bovis* BCG were identical to the RD1, RD2 and RD3 regions defined by the Stover team (Mahairas et al., 1996). Thus, by retaining the preceding nomenclature the inventors called the other 7 deletions of the *M. bovis* BCG/*M. bovis* genome, RD4, RD5, RD6, RD7, RD8, RD9 and RD10.

Other deletions have been found to be specific to the *M. tuberculosis* genome, it being understood that the "corresponding" sequences were present in *M. bovis* BCG/*M. bovis*; they were called RvD1 and RvD2 (tables 1 and 2).

The RD5-RD10, RvD1 and RvD2 deletions allowed the inventors to identify thoroughly the dynamics of the genome in the tubercle bacillus and gave information relating to the genetic bases of the phenotypic differentiation of the complex. The identification of RvD1 and RvD2 as deletions of the *M. tuberculosis* H37Rv genome shows that the deletion process does not function in a single direction, and the loss of information can therefore occur both in bovine strains and in human strains. It is observed that 8 of the 10 deletions detected are located in a region of the chromosome where termination of replication probably occurs.

The inventors then, within each deleted region, identified several ORFs (or open reading frames) or

FOI 60-2259260

genes and they tried to determine the putative function of each of them (table 1).

The subject of the present invention is therefore  
5 nucleotide sequences deleted from the genome of  
*M. bovis* BCG/*M. bovis* and present in the genome of  
*M. tuberculosis* or conversely chosen from the following  
ORFs and genes: Rv2346c, Rv2347c, Rv2348c, *plcC*, *plcB*,  
*plcA*, Rv2352c, Rv2353c, Rv3425, Rv3426, Rv3427c,  
10 Rv3428c, Rv1964, Rv1965, *mce3*, Rv1967, Rv1968, Rv1969,  
*lprM*, Rv1971, Rv1972, Rv1973, Rv1974, Rv1975, Rv1976c,  
Rv1977, *ephA*, Rv3618, Rv3619c, Rv3620c, Rv3621c,  
Rv3622c, *lpqG*, *cobL*, Rv2073c, Rv2074, Rv2075, *echA1*,  
Rv0223c, RvD1-ORF1, RvD1-ORF2, Rv2024c, *plcD*, RvD2-  
15 ORF1, RvD2-ORF2, RvD2-ORF3, Rv1758.

The expression "nucleotide sequence" according to the  
present invention is understood to mean a double-  
stranded DNA, a single-stranded DNA and products of  
20 transcription of said DNAs.

More particularly, the nucleotide sequences listed  
above are grouped into nucleotide regions according to  
the following distribution:

- 25
- RD5: Rv2346c, Rv2347c, Rv2348c, *plcC*, *plcB*, *plcA*,  
Rv2352c, Rv2353c,
  - RD6: Rv3425, Rv3426, Rv3427c, Rv3428c,
  - RD7: Rv1964, Rv1965, *mce3*, Rv1967, Rv1968, Rv1969,  
30 *lprM*, Rv1971, Rv1972, Rv1973, Rv1974, Rv1975,  
Rv1976c, Rv1977,
  - RD8: *ephA*, Rv3618, Rv3619c, Rv3620c, Rv3621c,  
Rv3622c, *lpqG*,
  - RD9: *cobL*, Rv2073c, Rv2074, Rv2075,
  - 35 - RD10: *echA1*, Rv0223c,
  - RvD1: RvD1-ORF1, RvD1-ORF2, Rv2024c
  - RvD2: *plcD*, RvD2-ORF1, RvD2-ORF2, RvD2-ORF3,  
Rv1758.

0936523-091401

Advantageously, 3 of the deletions (RD5, RD6 and RD8) contain 6 genes encoding PE and PPE proteins. As it has been suggested that these proteins have a possible role in antigenic variation (Cole et al., 1998), it can be deduced therefrom that these loci may represent sites of hypervariability between the tubercle strains.

At least 9 proteins capable of being exported or exposed at the surface are encoded by RD4 to RD10, which indicates that these polypeptides perhaps have a major role in the immune recognition of the bacillus. It has indeed been shown that secreted polypeptides can have a potential stimulatory role in the immune system and they are capable of playing a role of antigens known to become involved during the early stage of infection (Elhay et al., 1998; Horwitz et al., 1995; Rosenkrands et al., 1998).

The fact that RD5 and RD6 contain genes encoding proteins belonging to the ESAT-6 family, 14 of which are organized into 11 distinct loci, is particularly significant (F. Tekaia, S. Gordon, T. Garnier, R. Brosch, B.G. Barrell and S.T. Cole, submitted). ESAT-6 is a major T cell antigen which appears to be secreted by the virulent tubercle bacillus independently of the signal peptide (Harboe et al., 1996). It accumulates in the extracellular medium during the early phases of growth and its gene is located in RD1, a region which is deleted from the genome of *M. bovis* BCG (Mahairas et al., 1996; Philipp et al., 1996). 3 of the 10 RD regions thus contain genes of the ESAT-6 family, which indicates that other sites of ESAT-6 genes can also give rise to deletions or rearrangements.

35

The genomic sequence of *M. tuberculosis* H37Rv has moreover revealed the presence of 4 highly related genes encoding phospholipase C enzymes called *plcA*, *plcB*, *plcC* and *plcD* (Cole et al., 1998). Phospholipase

09036523 091440  
T04T60" E259C660



C has been recognized as a major virulence factor in a number of bacteria including *Clostridium perfringens*, *Listeria monocytogenes* and *Pseudomonas aeruginosa* where it plays an intracellular role in the dissemination of bacterial cells, in intracellular survival and in cytolysis (Titball, 1993). The RD5 deletion includes 3 genes (*plcA*, *plcB* and *plcC*), this region being absent from *M. bovis*, *M. bovis* BCG and *M. microti*. The detection of the phospholipase activity in *M. tuberculosis*, *M. microti* and *M. bovis* but not in *M. bovis* BCG has been previously described in (Johansen et al., 1996; Wheeler and Ratledge, 1992) as well as the role of the enzymes encoded by *plcA* and *plcB* (also known under the name *mpcA* and *mpcB*) in the hydrolysis both of phosphatidylcholine and sphingomyelin. The levels of phospholipase C activity which are detected in *M. bovis* are considerably less than those observed in *M. tuberculosis* which are in agreement with the loss of *plcABC*, the sphingomyelinase activity still being detectable. The sequence data presented here show that full-length phospholipase is encoded by the *plcD* gene in *M. bovis* BCG-Pasteur and that its considerable sequence similarity with the products of *plcA* and *plcB* indicates that it is probably endowed both with phospholipase activity and with a sphingomyelinase activity. It is therefore probable that *plcD* may be responsible for the residual phospholipase C activity in strains exhibiting the RD5 deletion, such as *M. bovis*, although it is difficult to link this interpretation to the observed absence of phospholipase C in spite of the presence of sphingomyelinase in the *M. bovis* BCG strain used in other studies (Johansen et al., 1996; Wheeler and Ratledge, 1992). Studies of expression with the cloned *plcD* gene ought to clarify this point.

The *mce* gene has been described by the Riley team as encoding a putative protein of *M. tuberculosis* of the invasin type, whose expression in *E. coli* allows the

invasion of HeLa cells (Arruda et al., 1993). Three other Mce proteins have been identified as part of the genome sequencing project with their gene occupying the same position in the four large highly conserved operons comprising at least eight genes (Cole et al., 1998; Harboe et al., 1996). It is difficult to deduce the effects of the loss of *mce3* (RD7) on *M. bovis*, *M. microti* and *M. bovis* BCG because of the fact that the remaining three copies of *mce* could complement any loss of activity, unless the operons are differently expressed. However, it is of interest to note that RD7 is absent from certain members of the *M. tuberculosis* complex which are not virulent for humans, suggesting that RD7 can play a specific role in human disease.

The genome of *M. tuberculosis* H37Rv also encodes six proteins (Eph-A-F) which show similarity with epoxide hydrolases whereas at least 21 enoyl-CoA hydratases (EchA1-21) and multiple aldehyde dehydrogenases are present (Cole et al., 1998). The loss of *epHA* (RD8), *echA1* and the aldehyde dehydrogenase encoded by Rv0223c (RD10) in *M. bovis* BCG/*M. bovis* can therefore be compensated by other enzymes although the substrate specificity of the *M. tuberculosis* enzymes is unknown. The epoxide hydrolases are generally considered as detoxifying enzymes; a recent report has again showed that they play a role in the activation of leukotoxins (Moghaddam et al., 1997), a toxic fatty acid produced by the leukocytes which are involved in respiratory distress syndrome in adults. However, the question of knowing if the *M. tuberculosis* epoxide hydrolases can chemically modify host chemokines is without response. Alternatively, they can play a role in lipid detoxification of the products of peroxidation which are generated by oxygen radicals from activated macrophages.

RD9 is a region deleted from the genomes of *M. africanum*, *M. bovis*, *M. bovis* BCG and *M. microti*

09036523 091404

compared to *M. tuberculosis*. Consequently, in contrast to the other RD regions, the location of *M. africanum* is close to *M. bovis*, which indicates the presence of this strain between *M. tuberculosis* and *M. bovis* (Heifets and Good, 1994). Similarly, the RD4 region can differentiate *M. microti* from the bovine strains (table 2).

The proteins encoded by RD4 to RD10 can therefore have antigens of interest, allowing discrimination between individuals vaccinated with BCG and patients infected with *M. tuberculosis*.

Thus, the subject of the present invention is also a method for the discriminatory detection and identification of *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample, comprising the following steps:

- a) isolation of the DNA from the biological sample to be analyzed or production of a cDNA from the RNA of the biological sample,
- b) detection of the DNA sequences of the mycobacterium present in said biological sample,
- c) analysis of said sequences.

Preferably, in the context of the present invention, the biological sample consists of a fluid, for example human or animal serum, blood, a biopsy, bronchoalveolar fluid or pleural fluid.

Analysis of the desired sequences may, for example, be carried out by agarose gel electrophoresis. If the presence of a DNA fragment migrating to the expected site is observed, it can be concluded that the analyzed sample contained microbacterial DNA. This analysis can also be carried out by the molecular hybridization

technique using a nucleic probe. This probe will be advantageously labeled with a nonradioactive (cold probe) or radioactive element.

5 Advantageously, the detection of the mycobacterial DNA sequences will be carried out using nucleotide sequences complementary to said DNA sequences. By way of example, they may include labeled or nonlabeled nucleotide probes; they may also include primers for  
10 amplification.

The amplification technique used may be PCR but also other alternative techniques such as the SDA (Strand Displacement Amplification) technique, the TAS  
15 technique (Transcription-based Amplification System), the NASBA (Nucleic Acid Sequence Based Amplification) technique or the TMA (Transcription Mediated Amplification) technique.

20 The primers in accordance with the invention have a nucleotide sequence chosen from the group comprising SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11,  
25 SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, and SEQ ID No. 18 with:

- the pair SEQ ID No. 1/SEQ ID No. 2 specific for RD4,
- 30 - the pair SEQ ID No. 3/SEQ ID No. 4 specific for RD5,
- the pair SEQ ID No. 5/SEQ ID No. 6 specific for RD6,
- the pair SEQ ID No. 7/SEQ ID No. 8 specific for  
35 RD7,
- the pair SEQ ID No. 9/SEQ ID No. 10 specific for RD8,
- the pair SEQ ID No. 11/SEQ ID No. 12 specific for RD9,

0936523-091401  
T04T60-E259E660

- the pair SEQ ID No. 13/SEQ ID No. 14 specific for RD10,

- the pair SEQ ID No. 15/SEQ ID No. 16 specific for RvD1, and

5       - the pair SEQ ID No. 17/SEQ ID No. 18 specific for RvD2,

In a variant, the subject of the invention is also a method for the discriminatory detection and  
10 identification of *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in the biological sample comprising the following steps:

- 15       a) bringing the biological sample to be analyzed into contact with at least one pair of primers as defined above, the DNA contained in the sample having been, where appropriate, made accessible to the hybridization beforehand,
- 20       b) amplification of the DNA of the mycobacterium,
- c) visualization of the amplification of the DNA fragments.

The amplified fragments may be identified by agarose or polyacrylamide gel electrophoresis by capillary  
25 electrophoresis or by a chromatographic technique (gel filtration, hydrophobic chromatography or ion-exchange chromatography). The specification of the amplification may be controlled by molecular hybridization using probes, plasmids containing these sequences or their  
30 product of amplification.

The amplified nucleotide fragments may be used as reagent in hybridization reactions in order to detect the presence, in a biological sample, of a target  
35 nucleic acid having sequences complementary to those of said amplified nucleotide fragments.

These probes and amplicons may be labeled or otherwise with radioactive elements or with nonradioactive molecules such as enzymes or fluorescent elements.

5 The subject of the present invention is also a kit for the discriminatory detection and identification of *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample comprising the following components:

- 10 a) at least one pair of primers as defined above,  
b) the reagents necessary to carry out a DNA amplification reaction,  
c) optionally, the necessary components which make it possible to verify or compare the sequence  
15 and/or the size of the amplified fragment.

Indeed, in the context of the present invention, depending on the pair of primers used, it is possible to obtain very different results. Thus, the use of  
20 primers which are internal to the deletion, are described in the present invention for RD4, RD5 and RD8, is such that no amplification product is detectable in *M. bovis* BCG. However, the use of primers external to the region of deletion does not necessarily  
25 give the same result, as regards for example the size of the amplified fragment, depending on the size of the deleted region in *M. bovis* BCG. Thus, the use of the pair of primers SEQ ID No. 5/SEQ ID No. 6 for the detection of RD6 is likely to give rise to an amplicon  
30 in *M. bovis* BCG of about 3 801 bp whereas the use of the pair of primers SEQ ID No. 11/SEQ ID No. 12 for the detection of RD9 will give rise in *M. bovis* BCG to an amplicon of about 1 018 bp.

35 The subject of the invention is also the use of at least one pair of primers as defined above for the amplification of DNA sequences of *M. bovis* BCG/*M. bovis* or *M. tuberculosis*.

093623-091401  
FBI/DOJ-E2552660

0936523 091401

The benefit of the use of several pairs of primers will be quite obviously to cross the results obtained with each of them in order to refine the result of the analysis. Indeed, when it is indicated, in the context of the present invention, that some deletions are specific to *M. bovis* BCG/*M. bovis*, that is not completely accurate since some of them are also found in *M. microti* OV254, in *M. tuberculosis* CSU#93 and in *M. africanum* as well as certain clinical isolates (table 2). Thus, the use of the pair of primers SEQ ID No. 1/SEQ ID No. 2 specific for the RD4 region will not give rise to amplicons of normal size with *M. bovis* BCG/*M. bovis* in the biological sample. On the other hand, if the pair of primers used is SEQ ID No. 5/SEQ ID No. 6 specific for RD6 and that amplicons of normal size are not found, it will not be possible, from this result only, to discriminate between the presence, in the biological sample, of *M. bovis* BCG/*M. bovis*, *M. microti* OV254 and *M. tuberculosis* CSU#93.

The discrimination will be more radical when it will involve determining if the mycobacterium present in the biological sample to be analyzed is *M. bovis* BCG/*M. bovis* or *M. tuberculosis* H37Rv because the pairs of primers SEQ ID No. 15/SEQ ID No. 16 and SEQ ID No. 17/SEQ ID No. 18 are specific only for *M. tuberculosis* H37Rv. Consequently, the absence of amplicon of normal size during the use of either of these pairs of primers may be considered as indicative of the presence of *M. tuberculosis* H37Rv in the biological sample analyzed.

The subject of the present invention is also the products of expression of all or part of the nucleotide sequences deleted from the genome of *M. bovis* BCG/*M. bovis* and present in *M. tuberculosis* or conversely as listed in table 1.

The expression "product of expression" is understood to mean any protein, polypeptide or polypeptide fragment resulting from the expression of all or part of the abovementioned nucleotide sequences and preferably exhibiting on least one of the following characteristics:

- capacity to export or secrete by a mycobacterium and or be induced or repressed during infection with mycobacterium, and/or
- capacity to induce, repress or modulate directly or indirectly a mycobacterial virulence factor, and/or
- capacity to induce an immunogenicity reaction directed against a mycobacterium, and/or
- capacity to be recognized by an antibody specific for a mycobacterium.

Indeed, the subject of the present invention is also a method for the discriminatory detection *in vitro* of antibodies directed against *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample, comprising the following steps:

- a) bringing the biological sample into contact with at least one product of expression as defined above,
- b) detecting of the antigen-antibody complex formed.

The subject of the invention is also a method for the discriminatory detection of a vaccination with *M. bovis* BCG or an infection by *M. tuberculosis* in a mammal, comprising the following steps:

- a) preparation of a biological sample containing cells, more particularly cells of the immune system of said mammal and more particularly still F cells,



- b) incubation of the biological sample of step a) with at least one product of expression in accordance with the present invention,
- c) detection of a cellular reaction indicating prior sensitization of the mammal to said product, in particular cell proliferation and/or synthesis of proteins such as gamma-interferon.

Cell proliferation may be measured, for example, by incorporating <sup>3</sup>H-Thymidine.

The invention also relates to a kit for the *in vitro* diagnosis of an *M. tuberculosis* infection in a mammal optionally vaccinated beforehand with *M. bovis* BCG comprising:

- a) a product of expression in accordance with the present invention,
- b) where appropriate, the reagents for the constitution of the medium suitable for the immunological reaction,
- c) the reagents allowing the detection of the antigen-antibody complexes produced by the immunological reaction,
- d) where appropriate, a reference biological sample (negative control) free of antibodies recognized by said product,
- e) where appropriate, a reference biological sample (positive control) containing a predetermined quantity of antibodies recognized by said product.

The reagents allowing the detection of the antigen-antibody complexes may carry a marker or may be capable of being recognized in turn by a labeled reagent, more particularly in the case where the antibody used is not labeled.

The subject of the invention is also mono- or polyclonal antibodies, their chimeric fragments or antibodies, capable of specifically recognizing a product of expression in accordance with the present invention.

The present invention therefore also relates to a method for the discriminatory detection of the presence of an antigen of *M. bovis* BCG/ *M. bovis* or *M. tuberculosis* in a biological sample comprising the following steps:

- a) bringing the biological sample into contact with an antibody in accordance with the invention,
- b) detecting the antigen-antibody complex formed.

The invention also relates to the kit for the discriminatory detection of the presence of an antigen of *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample comprising the following steps:

- a) an antibody in accordance with the invention,
- b) the reagents for constituting the medium suitable for the immunological reaction,
- c) the reagents allowing the detection of the antigen-antibody complexes produced by the immunological reaction.

The abovementioned reagents are well known to a person skilled in the art who will have no difficulty adapting them to the context of the present invention.

The subject of the invention is also an immunological composition, characterized in that it comprises at least one product of expression in accordance with the invention.

Advantageously, the immunological composition in accordance with the invention enters into the composition of a vaccine when it is provided in combination with a pharmaceutically acceptable vehicle and optionally with one or more immunity adjuvant(s) such as alum or a representative of the family of muramylpeptides or incomplete Freund's adjuvant.

The invention also relates to a vaccine comprising at least one product of expression in accordance with the invention in combination with a pharmaceutically compatible vehicle and, where appropriate, one or more appropriate immunity adjuvant(s).

Standard knowledge on the evolution of the *M. tuberculosis* complex is based on the hypothesis that *M. tuberculosis* is derived from *M. bovis* (Sreevatsan et al., 1997). However, a distribution of RD1 to RD10 among the tuberculous complex suggests that a linear evolution of *M. tuberculosis* from *M. bovis* is too simplistic. It appears, indeed, in a more probable manner, that the two bacilli are derived from a common strain, that the deletions therefore reflect the adaptation of the bacilli to their particular niche, that is to say that the loss of RD4 to RD10 probably helped *M. bovis* to become a more potent pathogenic agent for bovines than *M. tuberculosis*. Functional genomic studies will determine which role these deletions play in the phenotypic differentiation of the tuberculous complex.

Finally, the inventors have detected, still by comparing the BAC of *M. tuberculosis* H37Rv and the BAC of *M. bovis* BCG, two duplications in the genome of *M. bovis* BCG-Pasteur, called DU1 and DU2. They are duplications of regions of several tens of kilobases which appear to be absent both from the *M. bovis* and *M. tuberculosis* H37Rv type strain. The detection of these two duplications was made following digestion of

09333 0340  
T04T60 "E25E660

the same clones for each BAC with *Hind*III and analysis on a pulsed-filled electrophoresis gel (PFGE). These observations have been confirmed by hybridization of the digested chromosomal DNA derived from *M. bovis* BCG, from the type strain of *M. bovis* and *M. tuberculosis* H37Rv with selected probes covering the duplicated regions. Primers specific for the rearranged regions were prepared and tested on the genomic DNA from additional isolates of *M. bovis* BCG and *M. tuberculosis*.

It was determined that DU1 and DU2 were present in three strains of *M. bovis* BCG including in *M. bovis* BCG-Pasteur and absent from three other substrains of *M. bovis* BCG.

These two duplications are also absent from the type strain of *M. bovis* and *M. tuberculosis* H37Rv.

Thus, still in the context of the present invention in relation to the discriminatory detection of *M. bovis* or *M. tuberculosis*, the subject of the invention is also a method for the discriminatory detection and identification of *M. bovis* BCG or *M. tuberculosis* in a biological sample comprising the following steps:

- digestion, with a restriction enzyme, of at least part of the genome of the mycobacterium present in a biological sample to be analyzed, and
- analysis of the restriction fragments thus obtained.

The digestion with the restriction enzyme may indeed be carried out either on the entire genome of the mycobacterium, or on one or more clones of the library produced from the genome in question.

Preferably, the restriction enzyme used in the context of the abovementioned method is *HindIII*.

As regards the analysis of restriction fragments, it may consist in counting said fragments and/or in determining their length. Indeed, as is explained below, *HindIII* digestion of *M. bovis* BCG gives rise to one fragment more than those obtained after *HindIII* digestion of the genome of *M. tuberculosis* H37Rv. The number of fragments thus obtained may also be complemented by the determination of their length. This may be carried out by means of techniques well known to persons skilled in the art, for example on a pulsed filled electrophoresis gel (PFGE). It has thus been possible to determine that the additional fragment appearing after *HindIII* digestion of the genome of *M. bovis* BCG-Pasteur had a size of about 29 kb.

Another way of analyzing the restriction fragments resulting from the enzymatic digestion of the genome of the mycobacterium as described above consists in bringing said fragments into contact with at least one appropriate probe, covering for example the duplicated region, under hybridization conditions so as to then identify the number and size of the fragments which have hybridized. The probes used for this purpose may be labeled or nonlabeled according to techniques well known to persons skilled in the art.

Thus, the probe may be obtained by amplification of the genomic DNA with primers chosen from the group SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 33 or SEQ ID No. 34 with the pair:

- SEQ ID No. 31/SEQ ID No. 32 specific for DU1
- SEQ ID No. 33/SEQ ID No. 34 specific for DU2

It is also possible to analyze the fragments by carrying out amplification of the fragments obtained with primers chosen from the group SEQ ID No. 19,

5

- 10

15

## 20

30

35

**FIGURES 2A to 2F:** General view of the deleted regions RD5-RD10.

The regions deleted from the genome of *M. tuberculosis* are delimited by arrows with a sequence flanking each deletion. The ORFs (open reading frames) are represented by "directed" boxes showing the direction of transcription as described above (Cole et al., 1998). The putative functions and the families of the ORFs are described in table 3. The stop codons are indicated by small vertical bars.

10 **FIGURE 3:** Detection of the RD5 deletion.

Digestions of the Rv143 clone of the BAC with the endonucleases *EcoRI*, *PstI* and *StuI* revealed that fragments of 1.5 kb (*EcoRI*), 1.5 kb (*PstI*), 1.3 and 2.7 kb (*StuI*) show no binding with *M. bovis* or *M. bovis* BCG DNA probes (the absent bands are indicated by arrows). The size in kilobases (kb) is indicated on the left.

20 **FIGURE 4b:** The RvD1 and RvD2 regions

A. Size polymorphism in amplicons generated by flanking primers (i) RvD1 and (ii) RvD2. PCR reactions were carried out using the GeneAmp XL PCR kit (Perkin Elmer) with DNA templates of *M. tuberculosis* H37Rv, *M. bovis* and *M. bovis* BCG-Pasteur in combination with primers described in table 3. The size in kilobases is indicated on the left of each image.

30 B. Structure of the ORFs of the loci of RvD1 and RvD2. The sequence of the two loci was determined from *M. bovis* BCG Pasteur, the flanking sequence in *M. tuberculosis* H37Rv being shown. The putative functions of the ORFs are described in table 1 with vertical barriers representing the stop codons.

**FIGURE 5:** Duplicated region DU1 in *M. bovis* BCG-Pasteur compared with the same region in *M. tuberculosis* H37Rv.

009352-0940  
T04T60-E259E660

**FIGURE 6:** Duplicated region DU2 in *M. bovis* BCG-Pasteur compared to the same region in *M. tuberculosis* H37Rv

5 The present application is not limited to the above description and will be understood more clearly in the light of the examples below which should not in any manner be considered as limiting the present invention.

### EXAMPLES

#### 10 **1. PROCEDURES AND RESULTS**

##### Construction of an *M. bovis* BCG-Pasteur BAC library

15 Recent attempts for cloning very large inserts of mycobacterial DNA (120-180 kb) into the vector pBeloAC11 have resulted in failure (Brosch et al., 1998). To establish if this size determination was due to the vector pBeloBAC11, the inventors have tested in parallel the vector pBACe3.6 from BAC which uses the  
20 selection system *sacB* (Lawes and Maloy, 1995; Pelicic et al., 1996). Ligations carried out with fragments in the size ranges from 50 to 125 kb gave 5 to 10 times fewer transformants in pBACe3.6 than the control ligations using pBeloBAC11 (clones X). The size of an  
25 insert in the clones pBACe3.6 was approximately between the interval 40-100 kb, similar to what was observed for pBeloBAC11. This suggests that a size of about 120 kb is indeed the upper size limit for the feasibility of the cloning of mycobacterial DNA.

30

##### Definition of the minimum set of BCG BACs

100 clones randomly selected from pBeloBAC11 and pBACe3.6 libraries were sequenced at the ends to determine their position relative to the  
35 *M. tuberculosis* H37Rv chromosome (Cole et al., 1998). This gave a minimum network of clones on the genome but with a preferential group in the vicinity of the sole operon *rrn*, which was also observed during the construction of the *M. tuberculosis* BAC map (Brosch et

095523 094401  
"04460" E2556660



al., 1998). To fill the holes between the positioned clones, PCR primers were prepared, on the basis of the sequence of the complete *M. tuberculosis* genome, so as to screen the BAC pools for specific clones. Using this methodology, clones covering more than 98% of the genome were isolated and positioned on the sequence of the *M. tuberculosis* genome.

A minimum set of 57 *M. bovis* BCG clones was necessary to cover the genome (figure 1). 56 of these clones are from the library pBeloBAC11 and 1 is from the library pBACe3.6, namely XE015 (at about 680 kb). Because previous experience had shown that the *M. tuberculosis* clones based on pBeloBAC11 exhibited exceptional stability (Brosch et al., 1998), these clones were preferred to the less characterized pBACe3.6 system. The clone XE015 represents a region for which the pBeloBAC11 clones could not be found. Two regions of about 36-52 kb, covered by no clone, are located at about 2 660 kb and about 2 960 kb on the genome. Previously, the isolation of cosmids and of *M. tuberculosis* BAC clones which covered the region at about 2 960 kb posed problems (Brosch et al., 1998) suggesting that this region could contain genes which are detrimental to *E. coli*.

#### Use of BAC chips for detecting deletions in the *M. bovis* BCG genome

This involves the detection, from the *M. tuberculosis* H37Rv BAC library, of 63 clones covering 97% of the genome (Brosch et al., 1998). Analysis *in silico* of the sequence of the *M. tuberculosis* genome revealed that the digestion of these clones with either PvuII or *EcoRI* gave rise to a reasonable number of restriction fragments for each clone. The digested fragments migrated through agarose gels, gave rise to spots on membranes and were then hybridized with the <sup>32</sup>P-labeled genomic DNA of *M. bovis* BCG and *M. bovis*. The

restriction fragments which did not hybridize with the DNA probes were considered to be absent from the genomes of *M. bovis* or BCG. As the initial screening used only two enzymes, it is possible that other deletions passed unnoticed. However, it is probable that all the important deletions (> 5 kb) were detected by this approach.

From an analysis of the entire genome, 10 loci were identified which appeared to be absent from *M. bovis* BCG compared with *M. tuberculosis*. Hybridizations with the *M. bovis* genomic DNA revealed that 7 of these loci were also deleted in *M. bovis* compared with *M. tuberculosis*. Closer analysis revealed that the three deletions specific to *M. bovis* BCG were identical to the RD1-RD3 regions defined by the Stover team (Mahairas et al., 1996). Retaining the previous nomenclature, the 7 *M. bovis*/BCG deletions were designated RD4, RD5, RD6, RD7, RD8, RD9 and RD10 (figures 1 and 2). Sequencing reactions using the corresponding BAC clones as template were used to define precisely the terminal regions of the deletions (figure 2, table 1).

#### RD4

RD4 is a 12.7 kb deletion previously characterized as a region absent from *M. bovis* and *M. bovis* BCG of the Pasteur, Glaxo and Denmark substrains (Brosch et al., 1998). Among the proteins encoded by the 11 ORFs, some show resemblance with the enzymes involved in the synthesis of the lipopolysaccharides. To determine if RD4 was deleted only in the bovine strains, *M. africanum*, *M. microti*, *M. tuberculosis* CSU#93 and 27 clinical isolates of *M. tuberculosis* were examined for the presence of the locus (table 2). PCR reactions using primers internal to RD4 (table 3) generated only products in nonbovine strains.

#### RD5

RD5 has a size of 8 964 bp located between the genomic positions 2626067-2635031 (figure 3, table 1). The region contained 8 ORFs (table 1), three of them: *plcA*,  
5 *plcB* and *plcC*, encode phospholipase C enzymes whereas two others encode proteins belonging to the ESAT-6 and QILSS families respectively (Cole et al., 1998; F. Tekaia, S. Gordon, T. Garnier, R. Brosch, B.G. Barrell and S.T. Cole, submitted). ORF Rv2352c  
10 encodes a PPE protein which is a member of the large family of proteins in *M. tuberculosis* (Cole et al., 1998). Another protein of the PPE family (Rv2352c) is truncated in *M. bovis* BCG because of the fact that one of the deletions of the terminal parts is situated in  
15 the ORF. Searches in databases revealed that a segment of 3 013 bp of RD5 was virtually identical to the *mpt40* locus previously described, shown by Pattaroyo et al. to be absent in *M. bovis* and *M. bovis* BCG (Leao et al., 1995). Primers intended to amplify the internal part of  
20 RD5 (table 3) were used in the PCR reactions with the DNA derived from various tubercle bacilli. No amplicon was produced from *M. bovis*, *M. bovis* BCG and *M. microti* templates (table 2), indicting that *M. micoti* also lacks a RD5 locus.

25

#### RD6

RD6 was mapped at the level of the insertion sequence *IS1532*, an IS element which is absent in *M. microti*,  
*M. bovis* and *M. bovis* BCG (Gordon et al., 1998) (table  
30 1). The delimiting of the size of the deletion was complicated by the presence of repeat regions directly flanking the IS element and requiring the use of primers outside the repeat region (table 3). These primers amplified the products in *M. bovis* and *M. bovis*  
35 BCG which are about 5 kb smaller than the *M. tuberculosis* amplicon. Primer walking was used to precisely locate the junctions of deletions and revealed a deletion of 4 928 b in *M. bovis* and *M. bovis* BCG (genomic position of *M. tuberculosis* 3846807-

09036523.091401

3841879). Like the IS1532 element, it was determined that RD6 contained two genes encoding PPE proteins (Rv3425 and Rv3426) and part of Rv3424c whose function is unknown (table 1).

5

#### RD7

The RD2 deletion described in Mahairas et al. (Mahairas et al., 1996) was mapped in the *M. tuberculosis* Rv420 clone and the results obtained by the inventors have suggested the existence of an additional deletion in *M. bovis* BCG which is very close to RD2. Hybridizations were repeated using the *M. bovis* genomic DNA as probe since this strain contains RD2 sequences, thus simplifying the identification of other deleted fragments. This analysis (figure 2) revealed a 12 718 bp deletion in *M. bovis* BCG compared with *M. tuberculosis*, located 336 bp upstream of RD2, at positions 2208003-2220721 on the *M. tuberculosis* genome. The RD7 region contains 14 ORFs (table 3). 8 of them (Rv1964-1971) constitutes part of the operon with the putative invasine gene *mce3* (Cole et al., 1998). The ORFs Rv1968, Rv1969, Rv1971, Rv1973 and Rv1975 could encode possible proteins exported or expressed at the surface since they contain putative N-terminal signal sequences or membrane anchoring. They are all members of the Mce family and have common properties (Tekaiia et al., submitted). Interestingly, *Mce3* and Rv1968 contain the tripeptide "RGD" or Arg-Gly-Asp, a motif involved in cellular attachment (Ohno, 1995; Relman et al., 1989). Rv1977, which is truncated by RD7, encodes a protein exhibiting similarities (38.5% identity over 275 amino acids) with a hypothetical polypeptide and the PCC 6 803 strain of *Synechocystis*. PCR analysis (table 2) revealed that RD7 was present in 30 clinical isolates of *M. tuberculosis* as well as in *M. africanum* and *M. tuberculosis* CSU#93. The locus was however absent from *M. microti*, *M. bovis* and *M. bovis* BCG.

0036523 00401  
"04T60" E259E660

5  
10  
15

10

15

## 15

20

25

30

## 35

35

X318 has identified this region as being very different from the corresponding *M. tuberculosis* clones. The data relating to the terminal sequences from the clone X066 revealed that if its terminal sequence SP6 made it possible to position about 2 380 kb on the *M. tuberculosis* template, the terminal sequence T7 would not generate any significant similarity with any sequence of H37Rv, indicating that one end of X066 was internal to the DNA segment present in BCG but absent from H37Rv. Sequencing primers were used to walk along the BCG BAC clone X318 (figure 1) and revealed the insertion at the 2238724 bp position in the *M. tuberculosis* genome. Used in PCR reactions, the *M. bovis* BCG and *M. bovis* templates generated larger amplicons of about 5 kb than the product of *M. tuberculosis* H37Rv (figure 4A). The whole insert, designated RvD1, was sequenced from X318 BCG. The insert of 5 014 bp extended the *M. tuberculosis* Rv2024c ORF by 2.8 kb and contained an additional ORF, RvD1-ORF2, of 954 bp (table 1, Figure 4B). RvD1-ORF1 can be superposed over the 5' joining point of the deletion and extends inside the flanking DNA. FASTA analysis revealed that RvD1-ORF1 and ORF2 encode proteins exhibiting no significant similarity with other proteins in databases. Extended Rv2024c showed certain similarities (36.5% identity of 946 amino acids) with a *Helicobacter pylori* hypothetical protein (accession No. 025380). The loss of this sequence clearly had no consequence on the virulence of *M. tuberculosis* H37Rv since this strain is fully virulent in animal models. PCR analysis specific for the locus demonstrated its presence in several but not in all the clinical isolates and in all the BCG strains tested (table 2).

35

An ORF encoding a phospholipase, *plcD*, is interrupted by IS6110 in *M. tuberculosis* H37Rv (Cole et al., 1998). To determine if *plcD* was intact in other members of the tuberculous complex, primers flanking the insertion

0936523-09440  
T04T60-E259E660

site IS6110 (table 3) were used in PCR reactions with *M. bovis*, *M. bovis* BCG and *M. tuberculosis* H37Rv. This revealed polymorphism at the locus *plcD* where the *M. bovis* and *M. bovis* BCG amplicons were about 5 kb larger than the product of H37Rv (figure 4A). This deletion of about 5 kb in the *M. tuberculosis* H37Rv genome compared with *M. bovis* BCG was called RvD2. The sequencing of the *M. bovis* BCG BAC clone X086 revealed that RvD2 was positioned between bases 1987699-19890045 in the *M. tuberculosis* genome. The region comprises 6.5 kb and contains 3 ORFs encoding an unknown protein, an oxidoreductase and a membrane protein, and it extends the *plcD* gene in order to encode a product of 514 amino acids (Figure 4B, table 1).

## II. EXPERIMENTAL DATA

### Bacterial strains and plasmids

The strains of the *M. tuberculosis* complex (*Mycobacterium africanum*, *Mycobacterium microti*, *Mycobacterium tuberculosis*, *Mycobacterium bovis* and *Mycobacterium bovis* BCG) and substrains of *M. bovis* BCG (Danemark, Glaxo, Russe, Japonais, Pasteur and Moreau) were obtained from laboratory stalks (Unité de G.M.B., Institut Pasteur). *Mycobacterium tuberculosis* CSU#93 was received from John BELISLE, Department of Microbiology, Colorado State University, Fort Collins, CO 80523. Nonepidemic clinical isolates of *M. tuberculosis* were provided by Beate HEYM, Ambroise Paré hospital, 9 avenue Charles de Gaulle, 92104 BOULOGNE CEDEX, FRANCE. The BAC vectors pBeloBAC11 (Kim et al., 1996) and PBACe3.6 (Genbank accession No. U80929) were given by H. SHIZUYA, Department of Biology, California Institute of Technology, Pasadena, CA, and P. de JONG, Roswell Park Cancer Institute, Human Genetics Department, Buffalo, NY, respectively. The vectors and the derived recombinants were maintained in *E. coli* DH10B.

#### Preparation of the genomic DNA

The preparation of the genomic DNA in agarose cubes from *M. bovis* BCG Pasteur was carried out as previously indicated (Philipp et al., 1996; Philipp et al., 1996) but with two proteinase K digestions for 24 h each, rather than one digestion of 48 h. The cubes were stored in 0.2 M EDTA at 4°C and washed twice in 50 ml of Tris-EDTA (pH 8)/Triton X-100 (0.1%) at 4°C for 1 h, and then washed twice in 50 ml of a buffer of restriction enzyme Triton X-100 (0.1%) for 1 h at room temperature before use.

#### Construction of the BAC library

A DNA vector was prepared as previously indicated (Woo et al., 1994). Partial *Hind*III and *Eco*RI digestions of the DNA in agarose, for cloning into pBeloBAC11 and pBACe3.6 respectively, and then contour-clamped homogeneous electric field (CHEF) migration were carried out as previously described (Brosch et al., 1998). 5 zones, 50-75 kb, 75-100 kb, 100-125 kb and 150-170 kb were excized from agarose gels and stored in TE at 4°C. Ligations with the vectors pBeloBAC11 and pBACe3.6 and transformation in *E. coli* DH10B were carried out as previously described (Brosch et al., 1998). The pBeloBAC11 transformants were selected on LB agar containing 12.5 µg/ml of chloramphenicol, 50 µg/ml of X-gal and 25 µg/ml of IPTG, and were screened with white recombinant colonies. The pBACe3.6 transformants were selected on LB agar containing 12.5 µg of chloramphenicol and 5% of sucrose. The recombinant clones were subcultured, in duplicates, in 96-well microtiter plates containing a 2xYT medium with 12.5 µg of chloramphenicol and were incubated overnight at 37°C. An equal volume of glycerol at 80% was then added to the wells and a plate was stored at -80°C as master plate. The remaining plate was used to make sets of clones for screening purposes (see above).



Preparation of DNA from recombinants and examination of the size of the inserts

A recombinant carrying a DNA plasmid was prepared from 40 ml of culture and was grown on the 2xYT medium containing 12.5 µg of chloramphenicol as previously described (Brosch et al., 1998). 100-200 ng of DNA were digested with *DraI* (Gibco-BRL) and the restriction products were separated on a pulsed-field electrophoresis gel (PFGE) with an LKB-Pharmacia CHEF apparatus using a 1% (weight/volume) and a pulse of 4 seconds for 15 h at 6.25 V/cm. PFGE markers of average low size (New England Biolabs) were used as size standard. The sizes of the inserts were estimated after ethidium bromide staining and visualization with UV light.

Sequencing reactions

Sequencing reactions were carried out as previously indicated (Brosch et al., 1998). For clones isolated from the pBeloBAC11 library, the primers SP6 and T7 were used to sequence the ends of the inserts whereas for the clones pBACe3.6, the primers derived from the vector were used. The reactions were loaded onto 6% polyacrylamide gels and electrophoresis was carried out with a 373A or 377 automated DNA sequencer (Applied Biosystems) for 10 to 12 h. The reactions generally gave between 300 and 600 bp of readable sequences.

BAC chips

The overlapping clones from the pBeloBAC11 library of *M. tuberculosis* H37Rv (Brosch et al., 1998) were selected so that 97% of the *M. tuberculosis* genome was represented. The DNA prepared from these clones was digested with *EcoRI* (Gibco-BRL) or *PvuII* (Gibco-BRL) and was run on 0.8% agarose gels 25 cm in length, at a low voltage for 12 to 16 h. After staining and visualization under UV, the agarose gels were treated by the standard Southern method and the DNAs were transferred onto Hybond-C Extra nitrocellulose

membranes (Amersham). The DNA was fixed on the membrane by heating at 80°C for 2 h. The genomic DNA of *M. tuberculosis* H37Rv, *Mycobacterium bovis* ATCC 19210 and *M. bovis* BCG Pasteur was labeled with [ $\alpha$ -<sup>33</sup>P]dCTP using the Prime-It II kit (Stratagene). The probes were purified on a P10 column (Biorad) before use. Hybridizations were carried out as previously described (Philipp et al., 1996). The purified labeled probes were dissolved in a 5×SSC solution (1×SSC is 0.5 M sodium chloride; 0.015 M sodium citrate), and 50% (weight/volume) formamide. The hybridization was carried out at 37°C, and the membranes were washed for 15 min at room temperature in 2×SSC/0.1% SDS and then in 1×SSC/0.1% SDS and finally in 0.1×SSC/0.1% SDS. The results were interpreted from autoradiograms. In general, it was difficult to visualize on the autoradiograms the fragments of less than 1 kb, especially after repeated use of the membranes. The fragments larger than 1 kb gave clearer results. The clones which appeared to contain fragments with no counterpart in *M. bovis* BCG were subcultured for subsequent analyses. The genomic sequence allowed the establishment of restriction maps with the aim of determining the suspected regions of deletion, making it possible to select enzymes giving the best resolution of the regions. Clones could thus be digested with a second range of enzymes (generally *Pst*I and *Stu*I, with *Eco*RI included as a control) and hybridized in order to obtain a more accurate size of the deletion. The sequencing primers flanking the deletions were thus designated and used in the sequencing reactions with the corresponding BAC of *M. bovis* BCG used as template.

#### 35 PCR analysis

The primers used in the PCR reactions are listed in tables 3 and 4. The reactions for expected products of less than 3 kb were carried out with a standard *Taq* polymerase (Boehringer Mannheim). The reactions used

093653 091401

5 µl of 10×PCR buffer (100 mM β-mercaptoethanol, 600 mM Tris-HCl, pH 8.8), 20 mM MgCl<sub>2</sub>, 170 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 5 µl of nucleotide mixture at 20 mM, 0.2 µM of each primer, 10-50 ng of DNA template, DMSO at 10%, 0.5 unit of *Taq* polymerase and sterile distilled water to 50 µl. The heat cycles were carried out with a PTC-100 amplifier (MJ Inc.) with an initial denaturation step of 90 seconds at 95°C followed by 35 cycles of 30 seconds at 95°C, 1 min at 55°C and 2 min at 72°C.

10

The PCR reactions capable of giving rise to products greater than 3 kb were carried out using the PCR GeneAmp XL kit (Perkin Elmer). The reactions were initiated according to the manufacturer's instructions, with 0.8 mM Mg(OAc)<sub>2</sub>, 0.2 µM of each primer and 10-30 ng of DNA template per reaction. The heat cycles were carried out at 96°C for 1 min, then followed by 15 cycles in 2 stages at 94°C for 15 seconds and 70°C for 7 min, followed by 20 cycles in 2 stages at 94°C for 15 seconds and 70°C for 8 min plus 15 seconds per cycle.

#### Computer analysis

The data relating to the sequences were transferred from the automated ABI373A sequencer to the Sun or Digital work station and edited using the TED software from the Staden package. The edited sequences were compared with the inventors' database relating to *M. tuberculosis* (H37Rv.dbs) to determine the relative positions of the terminal sequences on the sequence of the *M. tuberculosis* genome. With this method, a map of the *M. bovis* BCG BAC clones was constructed using the *M. tuberculosis* H37Rv sequence as template.

To make the genomic comparison, digestions *in silico* using restriction enzymes were carried out with the NIP (Nucleotide Interpretation Program) software using the Staden package. The Display and Analysis program (DIANA) of the Sanger Centre, Cambridge, UK, was used to interpret the sequence data.

Accession numbers for the DNA sequences

The nucleotide sequences which flank each RD locus in *M. bovis* BCG have been deposited in the EMBL database.

- 5 The accession numbers for RD5, RD6, RD7, RD8, RD9 and RD10 are AJ007300, AJ131209, AJ007301, AJ131210, Y181604 and AJ132559, respectively. The sequences of RvD1 and RvD2 in *M. bovis* BCG have been deposited under the Nos. Y18605 and U18606 respectively.

10

Detection of the duplicated region DU1

DU1 was the first depleted region observed when the bands for *Hind*III digestion of the clone X038 of the BCG BAC and of the clone Rv13 of the H37Rv BAC were compared. The two clones X038 and Rv13 had identical terminal sequences, extending from position *Hind*III ~ 4 367 kb to the *Hind*III site ~ 0 027 kb (via 4411529 b) on the sequence of the genome of *M. tuberculosis* H37Rv (MTBH37RV), spanning the replication origin.

20

Analysis *in silico* of the *Hind*III restriction sites for the region given between ~ 4 367 kb and ~ 0 027 kb revealed a *Hind*III site at position ~ 4 404 kb. Consequently, digestion of these clones should show two restriction fragments plus the band specific for the vector at about 8 kb. That was the case for the H37Rv Rv13 clone. By contrast, the clone X038 of the BCG BAC showed three bands plus the band specific for the vector at about 8 kb, two of them were identical to the Rv13 scheme. The additional band has a size of about 29 kb. Additional PFGE analyses using *Dra*I revealed that X038 is indeed 29 kb longer than Rv13. For PCR screening of the BCG BAC pools using selected oligonucleotides, the inventors were able to identify three further clones X covering the parts of this genomic region in BCG: X585, X592, X703. The terminal sequence and the PFGE analysis showed that each of these clones contains an insert of a different size,

35

099353-0940  
T04760-E259E660

corresponding to the three bands observed in the results of digestion of X038 (Figure 5).

The terminal sequences are: X585 (~ 4 367-4 404 kb);  
5 X592 (~ 4 404-4404 kb); X703 (~ 4 404-0 027 kb). The sequences were repeated twice with the same results. The strange result according to which the clone X592 has T7 and SP6 and in the same genomic region could be explained by duplication of this genomic region in BCG  
10 and also give information on the extent of the rearrangement. Additional comparative restriction analyses of the clones X585, X592, X703 and X038 with *EcoRI* revealed that X592 and X703 have the same restriction pattern with the exception of a 10 kb band  
15 present in X703 but absent from X592. On the basis of these results, primers were prepared for the amplification of the joining region where the duplicated DNA segment joins the unique region.

20 PCR analysis with primers at 16.000 and at 4398.700 bp (SEQ ID No. 19 and 21) gave a product of an expected size from the clone X592 and also on the BCG-Pasteur genomic DNA. Sequencing of the PCR products obtained directly on the BAC DNA of the clone X592 revealed that  
25 the junction was indeed located at bases 16.732/4398.593 compared with the genomic sequence of H37Rv and that this genomic rearrangement resulted in the truncation of the *Rv3910* and *pknB* genes. However, since this rearrangement is a tandem duplication,  
30 intact copies of the two genes could be present in the neighboring regions. PCR analysis with flanking primers of the *Rv3920* and *pknB* genes confirmed this when the genomic DNA of BCG-Pasteur and of *M. tuberculosis* H37Rv were used. Additional proof of the rearrangement was  
35 obtained using a PCR fragment of 500 bp spanning the *oriC* region of H37Rv as <sup>32</sup>P-labeled probe in order to hybridize the products of digestion of the genomic DNA of *M. tuberculosis*, *M. bovis* and *M. bovis* BCG-Pasteur under the stringent conditions previously described

(Philipp et al., 1996). Whereas in *M. bovis* and *M. tuberculosis* a band having an average size of about 35 kb was detected, in *M. bovis* BCG-Pasteur two bands hybridized, one of approximately 35 kb and the other of 29 kb. In conclusion, DU1 corresponds to a tandem duplication of 29668 bp which results in merodiploidy for the *sigM-pabA* region (Rv3911-Rv0013).

PCR analysis using primers at 16.000F (SEQ ID No. 19) or 16.500F (SEQ ID No. 20) (sense primers) and at 4398.770R (SEQ ID No. 21) (reverse primer) on the genomic DNA of various BCG strains (Pasteur, Glaxo, Copenhagen, Russia, Prague, Japan) have revealed that products were only obtained from three strains, including *M. bovis* BCG-Pasteur. The other three substrates always gave negative results despite the confirmation of the positive controls.

As expected, the *M. bovis* and *M. tuberculosis* H37Rv type strains were also always negative. A summary of the mapping data is shown in figure 5.

The *dnaA-dnaN* region is generally regarded as the functional replication origin in mycobacteria since after insertion into plasmids whose own replication origin is absent, the capacity to autonomously replicate is restored. Since BCG-Pasteur is diploid for the *dnaA-dnaN* region, the inventors studied whether differences existed between the nucleotides of the two copies present on the two BAC X592 and X703 clones. Analysis of the BAC DNA sequence using primers of flanking and internal regions of the intergenic *dnaA-dnaN* region revealed no difference between the two copies of the minimal *oriC* region. Furthermore, these sequences were identical to those disclosed in the literature for this BCG strain. This study suggests that the two copies of *oriC* ought to be functional.

Detection of the duplicated region DU2

The second big genomic rearrangement observed in the *M. bovis* BCG-Pasteur chromosome was found by analyzing several BCG BAC clones covering a genomic region of about 200 kb (3 550-3 750 kb). Their sizes, evaluated by PFGE, did not conform to those expected from the H37Rv genome and data relating to the terminal sequences. Direct comparisons were complicated by the presence of an IS6110 element in this region of the *M. tuberculosis* H37Rv chromosome which led to a small RvD5 deletion.

The terminal sequences of BAC X495 were both located around the *Hind*III site at 3 594 kb, whereas the PFGE results showed that the clone has a size of about 106 kb, containing three *Hind*III fragments, of about 37.5 kb, about 37 kb and about 24 kb in addition to the vector. The 24 kb band was about 2 kb longer than the fragment corresponding to *Hind*III of 22 kb in Rv403. This observation led to the hypothesis that the genomic region at around 3 594 kb must have been duplicated, giving rise to the introduction of a novel *Hind*III site at the point where the clone X495 ends. To show this, several primers in the chromosomal region of 3 589 kb to 3 594 kb were tested for the sequencing of the BAC X495 DNA and a junction (JDU2A) was identified at bases 3690124/3590900 relative to the genomic sequence of H37Rv. This led to an interruption of the *lpdA* (Rv3303) gene but the PCR results indicated that an intact copy of this gene is present in the duplicated region.

Systematic analysis of other clones in the vicinity allowed the identification of 2 BACs independent of the BCG (X094 and X1026) which carried the same chromosomal fragment 3 594 to 3 749 kb. Although the terminal sequence data suggested that these clones had to have a size of about 155 kb, the size estimated by *Hind*III or *Dra*I digestions followed by PFGE separation were only about 100 kb. This difference indicated that the

inserts of clones X094 and X1026 probably extended from the repeated *Hind*III sites at 3 594 kb to the authentic *Hind*III site at position 3 749 kb, and that an internal deletion had taken place inside the duplicated unit.

5

This was confirmed by hybridization experiments under stringent conditions previously described on the genomic DNA, digested with *Hind*III, of *M. tuberculosis* H37Rv, *M. bovis* and BCG-Pasteur using the DNA of the radiolabeled X495 clone. The size of one of the bands which hybridized with this DNA in the *Hind*III profiles of *M. tuberculosis* H37Rv and *M. bovis* were about 22 kb, whereas the corresponding band in BCG was 24 kb exactly, which was observed with the BAC clones. Furthermore, the hybridization results showed that a band of 34 kb in the *Hind*III profile of the X094 clone also hybridized with the genomic DNA of the X495 clone, which confirmed that the X094 and X1026 clones contained the duplicated DNA of the genomic region covered by X495. PCR reactions and the sequence of the DNA of the X094 BAC clone allowed the identification of a second joining point JDU2B at an equivalent position at 3 608 471/3 671 535 in *M. tuberculosis* H37Rv. This confirmed that DU2 resulted from a direct duplication of a region of 99 225 bp corresponding to the sequences between positions 3 590 900 and 3 690 124 in the *M. tuberculosis* H37Rv genome, and an internal deletion of 63 064 bp then took place. The residual DU2 unit is thus 36 162 bp long, which is equivalent with the mapping data, and BCG-Pasteur is diploid for the *Rv3213c-Rv3230c* and *Rv3290c-Rv3302c* genes.

Finally, experiments involving PCR, PFGE mapping and sequencing of the terminal sequences with BAC X094 suggested that BCG-Pasteur contained additional DNA in the chromosomal region of the 3 691 to 3 749 kb *Hind*III site. Direct comparison with the *M. tuberculosis* Rv403 BAC clone allowed the detection of two additional *Hind*III sites in this region since the *Hind*III



fragments of 48 kb present in Rv403 (corresponding to  
fragment 3 691 to 3 749) were represented by two bands  
of 22 to 36 kb in BCG. This region of the  
*M. tuberculosis* H37Rv chromosome contains a copy of  
5 IS6110 which is not flanked by the characteristic  
direct repeat units of 3 bp. It is now clear that there  
were initially two copies of IS6110 which served as  
substrate for a recombination event. This gave rise to  
the deletion of a segment of 4 kb of the genome of  
10 *M. tuberculosis* H37Rv (RvD5), which is always present  
in BCG, as well as in *M. bovis* and the clinical  
isolates of *M. tuberculosis*. Analysis of the sequence  
of this region indicated that this 4 kb fragment  
contains two *Hind*III sites and that there is absent  
15 therefrom the IS6110 sequence which is present at this  
site in *M. tuberculosis* H37Rv. Using internal primers  
for RvD5 (table 4), the inventors obtained amplicons  
with the genomic DNA of all the *M. bovis* BCG strains  
tested, and the *M. bovis* strain, as well as with the  
20 DNA of clones X094 and X1026, but not with the  
*M. tuberculosis* H37Rv and H37Ra strains.

Experiments with multiple sets of primers (3689.500F  
(SEQ ID No. 22) or 3689.900F (SEQ ID No. 24) (sense)  
25 3591.000R (SEQ ID No. 23), 3591.500R (SEQ ID No. 25) or  
3592.000R (reverse)) to amplify the joining region at  
the level of the base 3690124/3590900 (described above)  
in various *M. bovis* BCG strains revealed that amplicons  
could only be obtained from *M. bovis* BCG-Pasteur and  
30 from two other BCG substrates, whereas the other BCG  
substrates gave no amplicon. Confirmation of the  
results may be obtained on *Hind*III spots hybridized  
with labeled DNA derived from the 3689500F-3690.000R  
region which ought to give rise to bands with  
35 rearranged BCG strains, one of them has a size of about  
24 kb, about 2 kb more than the corresponding band in  
the genomic digestions of *M. bovis* and *M. tuberculosis*.  
The second band of about 35 kb ought to be present only

09936523 "091401  
T04T60" E299E60

in the rearranged strains and not in *M. tuberculosis* H37Rv or the *M. bovis* type strain (figure 6).

The screening of clones of 2000 X and XE (Gordon et al., 1999) for BACs containing both JDU2A and JDU2B junctions, that is to say which cover the complete rearranged region allowed the identification of three BACs (X1070, XE377 and XE256) which produced amplicons with the two sets of primers. The inserts were estimated by PFGE to have a size of 95, 86 and 97 kb respectively. On the basis of these PCR results, data corresponding to the terminal sequences and the presence of three chromosomal *HindIII* fragments of 37, 36 and 24 kb, the inventors concluded that the X1070 clone overlaps the X495 clone. However, it contained a chromosomal *HindIII* fragment of 36 kb which was neither present in the X495 clone nor in the X094 clone and, with the terminal sequence data, this would suggest the presence of a third copy of the *HindIII* site at 3 594 kb in the rearranged region. New proof of this was obtained when the XE256 and XE377 clones obtained from an *EcoRI* library in pBACe3.6 were analyzed. Depending on the terminal sequence data, XE256 extends from the *EcoRI* site at 3 597 kb to the *EcoRI* site at 3 713 kb, and XE377 from the *EcoRI* site at 3 679 kb to the *EcoRI* site at 3 715 kb. The fact that these clones repeatedly gave amplicons for the two cited joining regions JDU2A and JDU2B was not in agreement with their size and their terminal sequences. However, these data were coherent with the fact that the region of 36 162 bp of DU2 was present not only as one but rather as two tandem copies. Hybridization (according to the method of Philipp et al., 1996) of the fragments of *HindIII* digested DNA of the XE256, X1070 and XE377 clones with a 0.5 kb probe of the 3 675 kb genomic region confirmed the PCR results. A 24 kb fragment of the X1070 clone hybridized, equivalent to that of the X495 clone, and a single 36 kb fragment which corresponds to an additional copy of DU2 was also

09936523-091401

present. Two fragments of 33 and 34 kb of the XE256 clone hybridized with the probe. The 33 kb fragment corresponds to a region which extends from the *Hind*III site present in the vector adjacent to the *Eco*RI cloning site to the nearest *Hind*III site in the mycobacterial insert, whereas the 34 kb fragment is identical to that which is also present in the X094 clone. The 33 kb fragment partially overlapped the X1070 clone whereas the 34 kb *Hind*III fragment was identical to that present in the X094 and XE377 clones.

These data indicate that two tandem copies of DU2 exist in the BCG-Pasteur genome. This was confirmed by the hybridizations of the products of digestion with *Hind*III of the genomic DNA of BCG-Pasteur, *M. tuberculosis* H37Rv and *M. bovis* since all hybridized with the 3 675 probe. As expected, only one band of 22 kb was observed with *M. tuberculosis* and *M. bovis* whereas three bands of 24, 34 and 36 kb were detected, by hybridization, in the BCG-Pasteur genome. However, the hybridization signal for the 36 kb fragment was very weak. The fact that the 24 and 36 kb bands present in the BAC X1070 clone hybridized with the 3 675 probe with the same intensity, whereas those in the genomic DNA of BCG-Pasteur do not, suggests that only a subpopulation of the BCG-Pasteur culture contains the second copy of DU2. Thus, the difference observed in the intensity of hybridization may reflect that the second copy of DU2 was only recently acquired and indicates variants which contain one or two copy or copies of DU2 probably exist in the same *M. bovis* BCG-Pasteur culture.

Similar results were obtained with the genomic DNA fragments digested with *Xba*I from *M. tuberculosis*, *M. bovis* and BCG-Pasteur which hybridize with the 3 675 probe. In the *M. tuberculosis* H37Rv digestion, the 3 675 probe hybridized with a 183 kb fragment (genomic position 3 646 kb to 3 829 kb). The corresponding

095523-0440  
T04T60-E259E660

*M. bovis* fragment was approximately 178 kb, this difference in size being due to the absence of several insertion elements which are present only in the 183 kb *M. tuberculosis* H37Rv genomic fragment. The product of digestion with BCG-Pasteur *Xba*I contained two fragments of 215 and 250 kb which hybridized with the 3 675 probe. These two fragments corresponded to the 178 kb fragment observed in the *M. bovis* genome increased by 36 or 72 kb because of the presence of one or two copies of DU2. It is of interest to note that the hybridization signal for the 250 kb fragment was less intense than the signal obtained for the 215 kb fragment, which confirms the previous observations with the products of digestion with *Hind*III.

These observations indicate that this region of the BCG genome is still dynamic and that a subpopulation of cells is triploid for the *Rv3213c-Rv3230c* and *Rv3290c-Rv3302c* genes. These comparative data between the sequence of the genome of *M. tuberculosis* H37Rv and of BCG-Pasteur indicate that BCG-Pasteur ought to be triploid for at least 58 genes, and that at one point of their evolution, their common ancestor contained duplicated copies of 60 additional genes which were lost when the deletion internal to DU2 occurred. Furthermore, the presence of DU1 and of DU2, and in particular the demonstration of the fact that DU2 is present in the form of two copies in a subpopulation of BCG-Pasteur, suggests that the tandem duplication process in BCG is still dynamic.

The invention therefore provides data which may make it possible to compare the various BCG strains with each other. Moreover, the invention shows the benefit of using mapping strategies with BACs as complement for sequencing the genome and allows the identification of possible drawbacks of projects which are based solely on the sequencing of clones by the "shot gun technique". Thus, without this BAC library, it is

highly probable that these complex genomic rearrangements in the *M. bovis* BCG strains would not have been detected. It is therefore an advantage of the present invention to provide data which allow the characterization and possibly the immunogenic and protective classifications of the various BCG strains which are currently used clinically and for vaccine applications, and to provide information which allow the specific identification of *M. tuberculosis* in relation to *M. bovis* and *M. bovis* BCG, or information which allow the specific identification of *M. bovis* BCG in relation to *M. bovis*. The present invention thus provides important information for the study and the epidemiology of tuberculosis, and for the subsequent studies of genomic rearrangements in the different bacteria. The technique developed in the present invention is exemplified by the results of the present invention and may be applied to other bacterial and/or parasite genomes.

Thus, the fact that *M. bovis* BCG-Pasteur and two other substrains of *M. bovis* BCG have a duplicated complement set of genes responsible for major processes such as, inter alia, cell division and signal translation, comprising two replication origins, is one of the surprising aspects revealed to the inventors by this approach to genetic comparisons.

Since the biological material is subject to changes, and given that BCG vaccination trials highly varied protection results (0-80%), it could be important to evaluate if this variation in the efficacy of protection may be partly attributed to the choice of the BCG substrain used.

It is therefore advisable to carry out additional investigations in order to determine if a correlation exists between genomic features and phenotypic variations among the various BCG substrains.

The BAC libraries have been deposited at the Collection  
Nationale de Culture de Microorganismes (CNCM), 25 rue  
du Dr Roux, 75724 PARIS CEDEX 15, France according to  
5 the provisions of the Budapest treaty.

BAC of <i>M. tuberculosis</i> H37Rv	Serial Number I1945
BAC of <i>M. bovis</i> BCG	Serial Number I2049

10

0995523-09440  
"04760" E259E560

TABLE 1: DESCRIPTION OF THE DELETIONS

DELETIONS	ORF/ GENE	POSITION® ON THE GENOME OF <i>M.</i> <i>TUBERCULOSIS</i> H37RV	SIZE OF THE PRODUCT	PUTATIVE FUNCTION OR FAMILY
RD5	Rv2346c	2625889-2626170	94 aa	ESAT-6 family
	Rv2347c	2626224-2626517	98 aa	QLISS family
	Rv2348c	2626655-2626978	108 aa	Unknown
	<i>plcC</i>	2627173-2628696	508 aa	Phospholipase
	<i>plcB</i>	2628782-2630317	512 aa	Phospholipase
	<i>plcA</i>	2630538-2632073	512 aa	Phospholipase
	Rv2352c	2632924-2634096	391 aa	PPE protein
	Rv2353c	2634529-2635590	354 aa	PPE protein
RD6	Rv3425	3842235-3842762	176 aa	PPE protein
	Rv3426	3843032-3843727	232 aa	PPE protein
	Rv3427c	3843884-3844636	251 aa	Transposase IS1532
	Rv3428c	3844737-3845966	410 aa	Transposase IS1532
RD7	Rv1964	2207698-2208492	265 aa	Integral membrane
	Rv1965	2208505-2209317	271 aa	Integral membrane
	<i>Mce3</i>	2209325-2210599	425 aa	Invasin-type protein, RGD motif
	Rv1967	2210599-2211624	342 aa	Exported protein
	Rv1968	2211624-2212853	410 aa	Exported protein, RGD motif
	Rv1969	2212853-2214122	423 aa	Exported protein
	<i>lprM</i>	2212853-2214122	377 aa	Lipoprotein
	Rv1971	2215255-2216565	437 aa	Exported protein
	Rv1972	2216590-2217162	191 aa	Membrane protein
	Rv1973	2217162-2217641	160 aa	Exported protein
	Rv1974	2217657-2218031	125 aa	Unknown
	Rv1975	2218050-2218712	221 aa	Exported protein
	Rv1976c	2218845-2219249	135 aa	Unknown
	Rv1977	2219752-2220795	348 aa	Unknown, Zn binding signature

TABLE 1 (CONTINUED)

RD8	<i>ephA</i>	4057730-4058695	322 aa	Epoxide hydrolase
	Rv3618	4058695-4059879	395 aa	Monooxygenase
	Rv3619c	4059984-4060265	94 aa	ESAT-6 family
	Rv3620c	4060295-4060588	98 aa	QLISS family
	Rv3621c	4060648-4061886	413 aa	PPE protein
	Rv3622c	4061899-4062195	99 aa	PE protein
	<i>lpqG</i>	4062524-4063243	240 aa	Lipoprotein
RD9	<i>cobL</i>	2328975-2330144	390 aa	Precorrin methylase
	Rv2073c	2330215-2330961	249 aa	Oxidoreductase
	Rv2074	2330991-2331401	137 aa	Unknown
	Rv2075	2331417-2332877	487 aa	Exported protein or membrane
RD10	<i>echAI</i>	265505-266290	262 aa	Enoyl-CoA hydratase
	Rv0223c	266302-267762	487 aa	Aldehyde dehydrogenase
RvD1	RvD1-ORF1	-	675 aa	Unknown
	RvD1-ORF2	-	318 aa	Unknown
	Rv2024c	-	1606 aa	Unknown
RvD2	<i>plcD</i>	-	514 aa	Phospholipase
	RvD2-ORF1	-	394 aa	Sugar transferase
	RvD2-ORF2	-	367 aa	Oxidoreductase
	RvD2-ORF3	-	945 aa	Membrane protein
	Rv1758	-	143 aa	Cutinase

5 \* As defined by Cole et al., Nature, 1998, 393, pages 537-544



TABLE 2: DISTRIBUTION OF THE DELETIONS AMONG THE *M. TUBERCULOSIS* COMPLEX

DELETION	<i>M. tuberculosis</i> H37Rv	<i>M.</i> <i>africanum</i>	<i>M. bovis</i>	<i>M. bovis</i> BCG	<i>M. microti</i> OV254	<i>M. tuberculosis</i> CSU#93	<i>M. tuberculosis</i> CLINICAL ISOLATES*
RD4	✓	✓	X	X	✓	✓	27/27
RD5	✓	✓	X	X	X	✓	ND
RD6	✓	✓	X	X	X	X	19/30
RD7	✓	✓	X	X	X	✓	30/30
RD8	✓	✓	X	X	X	✓	ND
RD9	✓	X	X	X	X	✓	8/8
RD10	✓	✓	X	X	X	✓	8/8
RvD1	X	✓	✓	✓	✓	✓	5/7
RvD2	X	✓	✓	✓	✓	✓	4/7

ND: Not determined: ✓ = the region is present, X = the region is deleted

\* Number of clinical isolates positive for the presence of a region

TABLE 3: PCR PRIMERS

DELETION	NAME OF THE PRIMER	SEQUENCE	EXPECTED PRODUCT SIZE
RD4*	277-32F 277-32R	ACATGTACGAGAGACGGCATGAG ATCCAACACGCAGCAACCAG	H37Rv: 1031 bp BCG: No product
RD5*	1cC-B.5P 1cC-B.3P	GATTCTCTGGACTGGCGTTG CCACCCAAGAAACCGCAC	H37Rv: 1623 bp BCG: No product
RD6	78-del1 78-del2	ACAAAATCGCCTCGTCGCC ACCTGTATTCTGTCGTTGCTGACC	H37Rv: 8729 bp BCG: 3801 bp
RD7	v420-flank1.F v420-flank2.R	GGTAATCGTGGCCGACAAG CTTGCGGCCCAATGAATC	H37Rv: 13068 bp BCG: 350 bp
RD8*	D8-ephA.F D8-ephA.R	GTGTGATTTGGTGAGACGATG GTTCTCTCTGACTAATCCAGGC	H37Rv: 678 bp BCG: No product
RD9	B2329.5F B2332.5R	CTGCCCCTCGTGC CGAA AGTGGCTCGGCACGCACA	H37Rv: 3048 bp BCG: 1018 bp
RD10	D10-264F D10-267R	CGCGAAAGAGGTCATCTAAAC GATGCTCAAGCCGTGCACC	H37Rv: 3024 bp BCG: 1121 bp
RvD1	Boli2268469.F Boli2269064.R	GCGCCACAAACGTACTATCTC GTTTCACCGGCTGTCGTTT	H37Rv: 595 pb BCG: 5595 bp
RvD2	28-IS6110B.5' 28-RHS.2	CCACACCGCAGGATTGGCAAG TCGAGTGCATGAACGCAACCGAG	H37Rv: 2007 bpt BCG: 7456 bp

\* = Primers internal to the deletion

† = Size including a copy of IS6110 not present in BCG

104760" E259E650

**TABLE 4: PRIMERS FOR THE IDENTIFICATION OF THE DEPLETED SAID REGIONS**

REGION	NAME OF THE PRIMER	SEQUENCE
DU1 JUNCTION	TB16.0F TB16.5F TB4398.7R	GAG CCA ACG ATG ATG ATG ACC GGT CAC GGT CGG TGT CGT C CAG AAC TGC AGG GGT GGT AC
DU2A JUNCTION	TB3689.5F TB3591.0R TB3689.9F TB3591.5R	CTA GTT GTT CAG CCG CGT CTT ACC GGG GTG TCG GCC AGT T TCG CGG CCA CCG TGC GTA A GGC GCC TAT GAC TGA TAC CC
DU2B JUNCTION	TB3608.0F TB3672.0R TB3671.7R	GAA CAG GGT CGC GGA GTC T TCG AGG AGG TCG AGT CCT GT GGG TTC ATG AGG TGC TAG GG
DETECTION PRIMERS RvD5	RvD5-intF RvD5-intR	GGG TTC ACG TTC ATT ACT GTT C CCT GCG CTT ATC TCT AGC GG
HYBRIDIZATION PROBE DU1	TB4411.0F TB0.3R	CCG GCC ACT CAC TGC CTT C ACG GTA GTG TCG TCG GCT TC
HYBRIDIZATION PROBE DU2 (probe 3 675)	TB3675.0F TB3675.5R	CCA ACA CCG TCA ACT ACT CGA ATC GCA GAA CTC CGG CGA CA
SEQUENCING OF THE REGION dnaA-dnaN	TB1.2F TB1.5F TB1.8F TB2.2R	CGA TCT GAT CGC CGA CGC C TCC GTC AGC GCT CCA AGC G GTC CCC AAA CTG CAC ACC CT AAT CCG GAA ATC GTC AGA CCG

104760-2259660

## REFERENCES

1. Arruda, S., Bomfim, G., Knights, R., Huima, B.T.  
5 and Riley, L.W. (1993) Cloning of an  
*M. tuberculosis* DNA fragment associated with entry  
and survival inside cells. *Science* **261**: 1454-1457.
2. Bloom, B.R. and Fine, P.E.M. (1994) The BCG  
experience: Implications for future vaccines  
10 against tuberculosis. In *Tuberculosis:  
Pathogenesis, Protection and Control*. Bloom, B.R.  
(eds). Washington D.C.: American Society for  
Microbiology, pp. 531-557.
3. Brosch, R., Gordon, S.V., Billault, A., Garnier,  
15 T., Eiglmeier, K., Soravito, C., Barrell, B.G. and  
Cole, S.T. (1998) Use of a *Mycobacterium  
tuberculosis* H37Rv bacterial artificial chromosome  
library for genome mapping, sequencing, and  
comparative genomics. *Infect Immun* **66**: 2221-2229.
- 20 4. Calmette, A. (1927) *La vaccination contre la  
tuberculose*, 250 p, Paris: Masson et Cie.
5. Chee, M., Yang, R., Hubbell, E., Berno, A., Huang,  
X.C., Stern, D., Winkler, J., Lockhart, D.J.,  
Morris, M.S. and Fodor, S.P. (1996) Accessing  
25 genetic information with high-density DNA arrays  
*Science* **274**: 610-614.
6. Cole, S.T., Brosch, R., Parkhill, J., Garnier, T.,  
Churcher, C., Harris, D. et al. (1988) Deciphering  
the biology of *Mycobacterium tuberculosis* from the  
30 complete genome sequence. *Nature* **393**: 537-544.
7. DeRisi, J.L., Iyer, V.R. and Brown, P.O. (1997)  
Exploring the metabolic and genetic control of  
gene expression on a genomic scale. *Science* **278**:  
610-614.
- 35 8. Elhay, M.J., Oettinger, T. and Andersen, P. (1998)  
Delayed-type hypersensitivity responses to ESAT-6  
and MPT64 from *Mycobacterium tuberculosis* in the  
guinea pig. *Infect Immun* **66**: 3454-3456.

0936523-09440  
T04T60-E29E650

9. Fine, P.E.M. (1994) Immunities in and to tuberculosis: implications for pathogenesis and vaccination. In *Tuberculosis: Back to the future*. Porter, J.D.H. and McAdam, K.P.W.J. (eds) Chichester: John Wiley and Sons Ltd., pp. 53-74.
10. Gordon, S.V., Heym, B., Parkhill, J., Barrell, B.G. and Cole, S.T. (1998) New insertion sequences and a novel repetitive element in the genome of *Mycobacterium tuberculosis*. *Microbiology* (in press)
11. Harboe, M., Oettinger, T., Wiker, H.G., Rosenkrands, I. and Andersen, P. (1996) Evidence for occurrence of the ESAT-6 protein in *Mycobacterium tuberculosis* and virulent *Mycobacterium bovis* and for its absence in *Mycobacterium bovis* BCG. *Infect Immun* **64**: 16-22.
12. Heifets, L.B. and Good, R.C. (1994) Current laboratory methods for the diagnosis of tuberculosis. In *Tuberculosis: Pathogenesis, Protection and Control*. Bllom, B.R. (eds). Washington D.C. American Society for Microbiology, pp. 85-110.
13. Horwitz, M.A., Lee, B.W., Dillon, B.J. and Harth, G. (1995) Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of *Mycobacterium tuberculosis*. *Proc Natl Acad Sci USA* **92**: 1530-1534.
14. Johansen, K.A., Gill, R.E. and Vasil, M.L. (1996) Biochemical and molecular analysis of phospholipase C and phospholipase D activity in mycobacteria. *Infect Immun* **64**: 3259-3266.
15. Kim, U.J., Birren, B.W., Slepak, T., Mancino, V., Boysen, C., Kang, H.L., Simon, M.I. and Shizuya, H. (1996) Construction and characterization of a human bacterial artificial chromosome library. *Genomics* **34**: 213-218
16. Lagranderie, M.R., Balazuc, A.M., Deriaud, E. and Leclerc, C.D. (1996) Comparison of immune responses of mice immunized with five different

*Mycobacterium bovis* vaccine strains. *Infect Immun* 64: 1-9.

17. Lawes, M. and Maloy, S. (1995) MudSacI, a transposon with strong selectable and counterselectable markers: use for rapid mapping of chromosomal mutations in *Salmonella typhimurium*. *J. Bacteriol* 177: 1383-1387.
18. Leao, S.C., Rocha, C.L., Murillo, L.A., Parra, C.A. and Patarroyo, M.E. (1995) A species-specific nucleotide sequence of *Mycobacterium tuberculosis* encodes a protein that exhibits hemolytic activity when expressed in *Escherichia coli*. *Infect Immun* 63: 4301-4306.
19. Mahairas, G.G., Sabo, P.J., Hickey, M.J., Singh, D.C. and Stover, C.K. (1996) Molecular analysis of genetic differences between *Mycobacterium bovis* BCG and virulent *M. bovis*. *J Bacteriol* 178: 1274-1282.
20. Moghaddam, M.F., Grant, D.F., Cheek, J.M., Greene, J.F., Williamson, K.C. and Hammock, B.D. (1997) Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. *Nature Med* 3: 562-6.
21. Ohno, S. (1995) Active sites of ligands and their receptors are made of common peptides that are also found elsewhere. *J Mol Evol* 40: 102-6.
22. Pelicic, V., Reyrat, J.M. and Gicquel, B. (1996) Expressions of the *Bacillus subtilis* sacB gene confers sucrose sensitivity on mycobacteria. *J Bacteriol* 178: 1197-9.
23. Philipp, W.J., Nair, S., Guglielmi, G., Lagranderie, M., Gicquel, B. and Cole, S.T. (1996) Physical mapping of *Mycobacterium bovis* BCG Pasteur reveals differences from the genome map of *Mycobacterium tuberculosis* H37Rv and from *M. bovis*. *Microbiology* 142:3135-3145.
24. Philipp, W.J., Poulet, S., Eiglmeier, K., Pascopella, L., Balasubramanian, V., Heym, B., Bergh, S., Bloom, B.R., Jacobs, W.J. and Cole, S.T. (1996) An integrated map of the genome of the

095523-094401

25. Relman, D.A., Domenighini, M., Tuomanen, E.,  
5 Rappuoli, R. and Falkow, S. (1989) Filamentous  
hemagglutinin of *Bordetella pertussis*: nucleotide  
sequence and crucial role in adherence. *Proc Natl  
Acad Sci USA* **86**: 2637-2641.

26. Rosenkrands, I., Rasmussen, P.B., Carnio, M.,  
10 Jacobsen, S., Theisen, M. and Andersen, P. (1998)  
Identification and characterization of a 29-  
kilodalton protein from *Mycobacterium tuberculosis*  
culture filtrate recognized by mouse memory  
effector cells. *Infect Immun* **66**: 2728-2735.

15 27. Sreevatsan, S., Pan, X., Stockbauer, K.E.,  
Connell, N.D., Kreiswirth, B.N., Whittam, T.S. and  
Musser, J.M. (1997) Restricted structural genes  
polymorphism in the *Mycobacterium tuberculosis*  
complex indicates evolutionarily recent global  
20 dissemination. *Proc Natl Acad Sci USA* **94**: 9869-  
9874.

28. Titball, R.W. (1993) Bacterial phospholipases C.  
*Microbiological Reviews* **57**: 347-66.

29. Wheeler, P.R. and Ratledge, C. (1992) Control and  
25 location of acyl-hydrolysing phospholipase  
activity in pathogenic mycobacteria. *J Gen  
Microbiol* **138**: 825-830.

30. Woo, S.S., Jiang, J., Gill, B.S., Paterson, A.H.  
and Wing, R.A. (1994) Construction and  
characterization of a bacterial artificial  
chromosome library of *Sorghum bicolor*. *Nuc Acids  
30 Res* **22**: 4922-31.

CLAIMS

1. Nucleotide or polynucleotide sequences deleted from the genome of *M. bovis* BCG/*M. bovis* and present in the genome of *M. tuberculosis* or conversely chosen from the following ORFs and genes: Rv2346c, Rv2347c, Rv2348c, *plcC*, *plcB*, *plcA*, Rv2352c, Rv2353c, Rv3425, Rv3426, Rv3427c, Rv3428c, Rv1964, Rv1965, *mce3*, Rv1967, Rv1968, Rv1969, *lprM*, Rv1971, Rv1972, Rv1973, Rv1974, Rv1975, Rv1976c, Rv1977, *ephA*, Rv3618, Rv3619c, Rv3620c, Rv3621c, Rv3622c, *lpqG*, *cobL*, Rv2073c, Rv2074, Rv2075, *echA1*, Rv0223c, RvD1-ORF1, RvD1-ORF2, Rv2024c, *plcD*, RvD2-ORF1, RvD2-ORF2, RvD2-ORF3, Rv1758.
2. The nucleotide or polynucleotide sequences as claimed in claim 1 grouped together in nucleotide regions RD5 to RD10 and RvD1 and RvD2 according to the following distribution:
- RD5: Rv2346c, Rv2347c, Rv2348c, *plcC*, *plcB*, *plcA*, Rv2352c, Rv2353c,
  - RD6: Rv3425, Rv3426, Rv3427c, Rv3428c,
  - RD7: Rv1964, Rv1965, *mce3*, Rv1967, Rv1968, Rv1969, *lprM*, Rv1971, Rv1972, Rv1973, Rv1974, Rv1975, Rv1976c, Rv1977,
  - RD8: *ephA*, Rv3618, Rv3619c, Rv3620c, Rv3621c, Rv3622c, *lpqG*,
  - RD9: *cobL*, Rv2073c, Rv2074, Rv2075c,
  - RD10: *echA1*, Rv0223c,
  - RvD1: RvD1-ORF1, RvD1-ORF2, Rv2024c
  - RvD2: *plcD*, RvD2-ORF1, RvD2-ORF2, RvD2-ORF3, Rv1758.
3. A method for the discriminatory detection and identification of *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample, comprising the following steps:

T04T60" E259E560



- 5
- a) isolation of the DNA from the biological sample to be analyzed or production of a cDNA from the RNA of the biological sample,
  - b) detection of the DNA sequences of the mycobacterium present in said biological sample,
  - c) analysis of said sequences with the nucleotide and polynucleotide sequences as claimed in claim 1 or 2.

10

4. The method as claimed in claim 3, in which the detection of the mycobacterial DNA sequences is carried out using nucleotide sequences complementary to said DNA sequences.

15

5. The method as claimed in claim 3 or 4, in which the detection of the mycobacterial DNA sequences is carried out by amplification of these sequences using primers.

20

6. The method as claimed in claim 5, in which the primers have a nucleotide sequence chosen from the group comprising SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, and SEQ ID No. 18 with:

- 25
- the pair SEQ ID No. 3/SEQ ID No. 4 specific for RD5,
  - 30 - the pair SEQ ID No. 5/SEQ ID No. 6 specific for RD6,
  - the pair SEQ ID No. 7/SEQ ID No. 8 specific for RD7,
  - 35 - the pair SEQ ID No. 9/SEQ ID No. 10 specific for RD8,
  - the pair SEQ ID No. 11/SEQ ID No. 12 specific for RD9,

- the pair SEQ ID No. 13/SEQ ID No. 14 specific for RD10,
  - the pair SEQ ID No. 15/SEQ ID No. 16 specific for RvD1, and
  - 5       - the pair SEQ ID No. 17/SEQ ID No. 18 specific for RvD2,
7.     The method as claimed in claim 6, in which the group from which the primers are chosen comprises,
- 10       in addition, the nucleotide sequences SEQ No. 1 and SEQ No. 2, the pair SEQ ID No. 1/SEQ ID No. 2 being specific to RD4.
8.     A method for the discriminatory detection and
- 15       identification of *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample, comprising the following steps:
- a) bringing the biological sample to be analyzed into contact with at least one pair of primers
- 20       as defined in claim 6 or 7, the DNA contained in the sample having been, where appropriate, made accessible to the hybridization beforehand,
- b) amplification of the DNA of the mycobacterium,
- 25       c) visualization of the amplification of the DNA fragments.
9.     A kit for the discriminatory detection and
- 30       identification of *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample comprising the following elements:
- a) at least one pair of primers as defined in claim 6 or 7,
- b) the reagents necessary to carry out a DNA
- 35       amplification reaction,
- c) optionally, the necessary components which make it possible to verify or compare the sequence and/or the size of the amplified fragment.

009522 0940  
T04T60 E259E660

10. The use of at least one pair of primers as defined in claim 6 or 7 for the amplification of a DNA sequence from *M. bovis* BCG/*M. bovis* or *M. tuberculosis*.
- 5
11. A product of expression of all or part of the nucleotide or polynucleotide sequences deleted from the genome of *M. bovis* BCG/*M. bovis* and present in *M. tuberculosis* or conversely as defined in claim 1.
- 10
12. A method for the discriminatory detection *in vitro* of antibodies directed against *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample, comprising the following steps:
- 15
- a) bringing the biological sample into contact with at least one product as defined in claim 11,
- b) detecting the antigen-antibody complex formed.
- 20
13. A method for the discriminatory detection of a vaccination with *M. bovis* BCG or an infection by *M. tuberculosis* in a mammal, comprising the following steps:
- 25
- a) preparation of a biological sample containing cells, more particularly cells of the immune system of said mammal and more particularly still T cells,
- b) incubation of the biological sample of step a) with at least one product as defined in claim 11,
- 30
- c) detection of a cellular reaction indicating prior sensitization of the mammal to said product, in particular cell proliferation and/or synthesis of proteins such as gamma-interferon.
- 35
14. A kit for the *in vitro* diagnosis of an *M. tuberculosis* infection in a mammal optionally

09936523-094401  
"FOHED" E2596660

vaccinated beforehand with *M. bovis* BCG comprising:

- a) a product as defined in claim 11,
- b) where appropriate, the reagents for the constitution of the medium suitable for the immunological reaction,
- c) the reagents allowing the detection of the antigen-antibody complexes produced by the immunological reaction,
- d) where appropriate, a reference biological sample (negative control) free of antibodies recognized by said product,
- e) where appropriate, a reference biological sample (positive control) containing a predetermined quantity of antibodies recognized by said product.

15. A mono- or polyclonal antibody, its chimeric fragments or antibodies, characterized in that they are capable of specifically recognizing a product as defined in claim 11.

16. A method for the discriminatory detection of the presence of an antigen of *M. bovis* BCG/ *M. bovis* or *M. tuberculosis* in a biological sample comprising the following steps:

- a) bringing the biological sample into contact with an antibody as claimed in claim 15,
- b) detecting the antigen-antibody complex formed.

17. A kit for the discriminatory detection of the presence of an antigen of *M. bovis* BCG/*M. bovis* or *M. tuberculosis* in a biological sample comprising the following steps:

- a) an antibody as claimed in claim 15,
- b) the reagents for constituting the medium suitable for the immunological reaction,

c) the reagents allowing the detection of the antigen-antibody complexes produced by the immunological reaction.

- 5 18. An immunological composition, characterized in that it comprises at least one product as defined in claim 11.
- 10 19. A vaccine, characterized in that it comprises at least one product as defined in claim 11 in combination with a pharmaceutically compatible vehicle and, where appropriate, one or more appropriate immunity adjuvants.
- 15 20. A method for the discriminatory detection and identification of *M. bovis* BCG or *M. tuberculosis* in a biological sample comprising the following steps:
- 20 - digestion with *Hind*III, of at least part of the genome of the mycobacterium present in a biological sample to be analyzed, and
- analysis of the restriction fragments thus obtained.
- 25 21. The method as claimed in claim 20, in which the analysis of the restriction fragments consists in counting said fragments and/or in determining their length.
- 30 22. Method of detection as claimed in either of claims 20 and 21, in which the analysis of the restriction fragments consists in bringing them into contact with at least one probe under stringent hybridization conditions and in
- 35 identifying the fragment parts or fragment hybridized.
23. A method as claimed in claim 22, characterized in that the probe is obtained by amplification of the

009999 09140  
T04T60 E259E60

genomic DNA with primers chosen from the group  
SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 33 or  
SEQ ID No. 34 with the pair:

- SEQ ID No. 31/SEQ ID No. 32 specific for DU1
- 5 - SEQ ID No. 33/SEQ ID No. 34 specific for DU2


24. Method according to claim 20, characterized in  
that amplification is carried out of the fragments  
obtained with primers chosen from the group  
10 SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21,  
SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24,  
SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27 and  
SEQ ID No. 28 with:

- SEQ ID No. 19, SEQ ID No. 20/SEQ ID No. 21  
15 specific for JDU1
- SEQ ID No. 22, SEQ ID No. 24/SEQ ID No. 23,  
SEQ ID No. 25 specific for JDU2A
- SEQ ID No. 26/SEQ ID No. 27, SEQ ID No. 28  
specific for JDU2B

20 25. The method as claimed in claim 20, characterized  
in that the fragments obtained are amplified with  
primers chosen from the group SEQ ID No. 35,  
SEQ ID No. 36, SEQ ID No. 37 and SEQ ID No. 38  
25 specific for DU1 and then to analyze them by  
sequencing.

TOP SECRET

Table 1. Characteristics of the study population	
Characteristic	Value
Number of subjects	100
Age (years)	65.2 ± 1.5
Gender (male/female)	50/50
Weight (kg)	75.2 ± 1.5
Height (cm)	175.2 ± 1.5
BMI (kg/m <sup>2</sup> )	24.2 ± 1.5
Diabetes (yes/no)	10/90
Hypertension (yes/no)	20/80
Hyperlipidemia (yes/no)	30/70
Smoking (yes/no)	40/60
Alcohol consumption (yes/no)	50/50
Family history of CVD (yes/no)	60/40
Previous CVD (yes/no)	10/90
Medication (yes/no)	20/80
Exercise (yes/no)	30/70
Diet (yes/no)	40/60
Stress (yes/no)	50/50
Sleep (yes/no)	60/40
Work (yes/no)	70/30
Education (yes/no)	80/20
Income (yes/no)	90/10
Marital status (yes/no)	100/0
Religion (yes/no)	100/0
Culture (yes/no)	100/0
Language (yes/no)	100/0
Gender (yes/no)	100/0
Age (yes/no)	100/0
Weight (yes/no)	100/0
Height (yes/no)	100/0
BMI (yes/no)	100/0
Diabetes (yes/no)	100/0
Hypertension (yes/no)	100/0
Hyperlipidemia (yes/no)	100/0
Smoking (yes/no)	100/0
Alcohol consumption (yes/no)	100/0
Family history of CVD (yes/no)	100/0
Previous CVD (yes/no)	100/0
Medication (yes/no)	100/0
Exercise (yes/no)	100/0
Diet (yes/no)	100/0
Stress (yes/no)	100/0
Sleep (yes/no)	100/0
Work (yes/no)	100/0
Education (yes/no)	100/0
Income (yes/no)	100/0
Marital status (yes/no)	100/0
Religion (yes/no)	100/0
Culture (yes/no)	100/0
Language (yes/no)	100/0
Gender (yes/no)	100/0
Age (yes/no)	100/0
Weight (yes/no)	100/0
Height (yes/no)	100/0
BMI (yes/no)	100/0
Diabetes (yes/no)	100/0
Hypertension (yes/no)	100/0
Hyperlipidemia (yes/no)	100/0
Smoking (yes/no)	100/0
Alcohol consumption (yes/no)	100/0
Family history of CVD (yes/no)	100/0
Previous CVD (yes/no)	100/0
Medication (yes/no)	100/0
Exercise (yes/no)	100/0
Diet (yes/no)	100/0
Stress (yes/no)	100/0
Sleep (yes/no)	100/0
Work (yes/no)	100/0
Education (yes/no)	100/0
Income (yes/no)	100/0
Marital status (yes/no)	100/0
Religion (yes/no)	100/0
Culture (yes/no)	100/0
Language (yes/no)	100/0
Gender (yes/no)	100/0
Age (yes/no)	100/0
Weight (yes/no)	100/0
Height (yes/no)	100/0
BMI (yes/no)	100/0
Diabetes (yes/no)	100/0
Hypertension (yes/no)	100/0
Hyperlipidemia (yes/no)	100/0
Smoking (yes/no)	100/0
Alcohol consumption (yes/no)	100/0
Family history of CVD (yes/no)	100/0
Previous CVD (yes/no)	100/0
Medication (yes/no)	100/0
Exercise (yes/no)	100/0
Diet (yes/no)	100/0
Stress (yes/no)	100/0
Sleep (yes/no)	100/0
Work (yes/no)	100/0
Education (yes/no)	100/0
Income (yes/no)	100/0
Marital status (yes/no)	100/0
Religion (yes/no)	100/0
Culture (yes/no)	100/0
Language (yes/no)	100/0
Gender (yes/no)	100/0
Age (yes/no)	100/0
Weight (yes/no)	100/0
Height (yes/no)	100/0
BMI (yes/no)	100/0
Diabetes (yes/no)	100/0
Hypertension (yes/no)	100/0
Hyperlipidemia (yes/no)	100/0
Smoking (yes/no)	100/0
Alcohol consumption (yes/no)	100/0
Family history of CVD (yes/no)	100/0
Previous CVD (yes/no)	100/0
Medication (yes/no)	100/0
Exercise (yes/no)	100/0
Diet (yes/no)	100/0
Stress (yes/no)	100/0
Sleep (yes/no)	100/0
Work (yes/no)	100/0
Education (yes/no)	100/0
Income (yes/no)	100/0
Marital status (yes/no)	100/0
Religion (yes/no)	100/0
Culture (yes/no)	100/0
Language (yes/no)	100/0
Gender (yes/no)	100/0
Age (yes/no)	100/0
Weight (yes/no)	100/0
Height (yes/no)	100/0
BMI (yes/no)	100/0
Diabetes (yes/no)	100/0
Hypertension (yes/no)	100/0
Hyperlipidemia (yes/no)	100/0
Smoking (yes/no)	100/0
Alcohol consumption (yes/no)	100/0
Family history of CVD (yes/no)	100/0
Previous CVD (yes/no)	100/0
Medication (yes/no)	100/0
Exercise (yes/no)	100/0
Diet (yes/no)	100/0
Stress (yes/no)	100/0
Sleep (yes/no)	100/0
Work (yes/no)	100/0
Education	



**Figure 1A**





Figure 1B




Demographics		Sociodemographics		Psychiatric History		Substance Use		Current Status	
Variable	Mean (SD)	Variable	Mean (SD)	Variable	Mean (SD)	Variable	Mean (SD)	Variable	Mean (SD)
Age	35.2 (12.5)	Gender	Male 65%	Previous Hospitalizations	2.1 (1.8)	Alcohol Use	1.5 (1.2)	Current Status	Stable 75%
Education	12.8 (2.1)	Marital Status	Married 45%	Previous Suicide Attempts	0.8 (1.5)	Drug Use	0.5 (0.8)	Current Status	Unstable 25%
Income	\$18,500 (15,000)	Employment	Unemployed 55%	Current Medications	3.2 (2.5)	Smoking	1.2 (0.8)	Current Status	Stable 60%
Religion	Christian 60%	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 40%
Marital Status	Single 35%	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Stable 55%
Employment	Unemployed 55%	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 45%
Health Insurance	Medicaid 50%	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Stable 65%
Family History	1.5 (1.2)	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 35%
Family History	1.5 (1.2)	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Stable 70%
Family History	1.5 (1.2)	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 30%
Family History	1.5 (1.2)	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Stable 68%
Family History	1.5 (1.2)	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 32%
Family History	1.5 (1.2)	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Stable 72%
Family History	1.5 (1.2)	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 28%
Family History	1.5 (1.2)	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Stable 70%
Family History	1.5 (1.2)	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 30%
Family History	1.5 (1.2)	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Stable 68%
Family History	1.5 (1.2)	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 32%
Family History	1.5 (1.2)	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Stable 70%
Family History	1.5 (1.2)	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 28%
Family History	1.5 (1.2)	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Stable 72%
Family History	1.5 (1.2)	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 30%
Family History	1.5 (1.2)	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Stable 68%
Family History	1.5 (1.2)	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 32%
Family History	1.5 (1.2)	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Stable 70%
Family History	1.5 (1.2)	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 28%
Family History	1.5 (1.2)	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Stable 72%
Family History	1.5 (1.2)	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 30%
Family History	1.5 (1.2)	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Stable 68%
Family History	1.5 (1.2)	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 32%
Family History	1.5 (1.2)	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Stable 70%
Family History	1.5 (1.2)	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 28%
Family History	1.5 (1.2)	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Stable 72%
Family History	1.5 (1.2)	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 30%
Family History	1.5 (1.2)	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Stable 68%
Family History	1.5 (1.2)	Health Insurance	Medicaid 50%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status	Unstable 32%
Family History	1.5 (1.2)	Health Insurance	Private 40%	Family History	1.5 (1.2)	Exercise	0.8 (0.5)	Current Status</	

REPLACEMENT SHEET (RULE 26)



**Figure 1C**

1. <i>Chlamydomonas reinhardtii</i> (CC-124) 2. <i>Chlamydomonas reinhardtii</i> (CC-124) 3. <i>Chlamydomonas reinhardtii</i> (CC-124) 4. <i>Chlamydomonas reinhardtii</i> (CC-124)		5. <i>Chlamydomonas reinhardtii</i> (CC-124) 6. <i>Chlamydomonas reinhardtii</i> (CC-124) 7. <i>Chlamydomonas reinhardtii</i> (CC-124) 8. <i>Chlamydomonas reinhardtii</i> (CC-124)		9. <i>Chlamydomonas reinhardtii</i> (CC-124) 10. <i>Chlamydomonas reinhardtii</i> (CC-124) 11. <i>Chlamydomonas reinhardtii</i> (CC-124) 12. <i>Chlamydomonas reinhardtii</i> (CC-124)	
1	2	3	4	5	6
7	8	9	10	11	12
13	14	15	16	17	18
19	20	21	22	23	24
25	26	27	28	29	30
31	32	33	34	35	36
37	38	39	40	41	42
43	44	45	46	47	48
49	50	51	52	53	54
55	56	57	58	59	60
61	62	63	64	65	66
67	68	69	70	71	72
73	74	75	76	77	78
79	80	81	82	83	84
85	86	87	88	89	90
91	92	93	94	95	96
97	98	99	100	101	102
103	104	105	106	107	108
109	110	111	112	113	114
115	116	117	118	119	120
121	122	123	124	125	126
127	128	129	130	131	132
133	134	135	136	137	138
139	140	141	142	143	144
145	146	147	148	149	150
151	152	153	154	155	156
157	158	159	160	161	162
163	164	165	166	167	168
169	170	171	172	173	174
175	176	177	178	179	180
181	182	183	184	185	186
187	188	189	190	191	192
193	194	195	196	197	198
199	200	201	202	203	204
205	206	207	208	209	210
211	212	213	214	215	216
217	218	219	220	221	222
223	224	225	226	227	228
229	230	231	232	233	234
235	236	237	238	239	240
241	242	243	244	245	246
247	248	249	250	251	252
253	254	255	256	257	258
259	260	261	262	263	264
265	266	267	268	269	270
271	272	273	274	275	276
277	278	279	280	281	282
283	284	285	286	287	288
289	290	291	292	293	294
295	296	297	298	299	300
301	302	303	304	305	306
307	308	309	310	311	312
313	314	315	316	317	318
319	320	321	322	323	324
325	326	327	328	329	330
331	332	333	334	335	336
337	338	339	340	341	342
343	344	345	346	347	348
349	350	351	352	353	354
355	356	357	358	359	360
361	362	363	364	365	366
367	368	369	370	371	372
373	374	375	3		



**Figure 1D**

RD5




Figure 2A




Figure 2B

FIG. 2C




Figure 2C

RD8




Figure 2D




Figure 2E






Figure 2F





**FIGURE 4A**





Figure 4b



*M. tuberculosis* H37Rv




FIGURE 5




FIGURE 6

## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first, and sole inventor (if only one name is listed below) or an original, first, and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**DELETED SEQUENCES IN M. BOVIS BCG/H. BOVIS OR M. TUBERCULOSIS, METHOD FOR DETECTING MYCOBACTERIA USING THESE SEQUENCES AND VACCINES**

the specification of which ☐ is attached and/or ☒ was filed on **March 16, 2000**  
or PCT International Application No. **FR00/00637**

as United States Application Serial  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT International application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119	
FRANCE	95 03250	March 16, 1999	<input checked="" type="checkbox"/> YES	<input type="checkbox"/> NO
			<input type="checkbox"/> YES	<input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:


Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
FR00/00637	March 16, 2000	Pending

I hereby appoint the following attorney and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP.**, Douglas B. Henderson, Reg. No. 20,291; Ford F. Farabow, Jr., Reg. No. 20,630; Arthur S. Garrett, Reg. No. 20,338; Donald R. Dunner, Reg. No. 19,073; Brian G. Brunsvold, Reg. No. 22,593; Tipton D. Jennings, IV, Reg. No. 20,645; Jerry D. Voight, Reg. No. 23,020; Laurence R. Heftler, Reg. No. 20,827; Kenneth E. Payne, Reg. No. 23,098; Herbert H. Mintz, Reg. No. 26,691; C. Larry O'Rourke, Reg. No. 26,014; Albert J. Santorelli, Reg. No. 22,610; Michael C. Elmer, Reg. No. 25,857; Richard H. Smith, Reg. No. 20,609; Stephen L. Peterson, Reg. No. 26,325; John M. Romany, Reg. No. 26,331; Bruce C. Zutter, Reg. No. 27,680; Dennis P. O'Reilly, Reg. No. 27,932; Allen M. Sokal, Reg. No. 26,693; Robert D. Bajelsky, Reg. No. 25,387; Richard L. Stroup, Reg. No. 28,478; David W. Hill, Reg. No. 28,220; Thomas L. Irving, Reg. No. 28,619; Charles E. Lipsey, Reg. No. 28,165; Thomas W. Winland, Reg. No. 27,605; Basil J. Lewis, Reg. No. 28,818; Martin I. Fuchs, Reg. No. 28,508; E. Robert Yoches, Reg. No. 30,120; Barry W. Graham, Reg. No. 29,924; Susan Haberman Griffen, Reg. No. 30,907; Richard B. Racine, Reg. No. 30,415; Thomas H. Jenkins, Reg. No. 30,857; Robert E. Converse, Jr., Reg. No. 27,432; Clair X. Mullen, Jr., Reg. No. 20,348; Christopher P. Foley, Reg. No. 31,354; John C. Paul, Reg. No. 30,413; Roger D. Taylor, Reg. No. 28,992; David M. Kelley, Reg. No. 30,953; Kenneth J. Meyers, Reg. No. 25,146; Carol P. Einaudi, Reg. No. 32,220; Walter Y. Boyd, Jr., Reg. No. 31,738; Steven M. Anzalone, Reg. No. 32,095; Jean B. Fordis, Reg. No. 32,984; Barbara C. McCurdy, Reg. No. 32,120; James K. Hammond, Reg. No. 31,964; Richard V. Burgujian, Reg. No. 31,744; Michael Jakes, Reg. No. 32,824; Dirk D. Thomas, Reg. No. 32,600; Thomas W. Banks, Reg. No. 32,719; Christopher P. Isaac, Reg. No. 32,616; Bryan C. Diner, Reg. No. 32,409; M. Paul Barker, Reg. No. 32,013; Andrew Chanho Sonu, Reg. No. 33,452; David S. Forman, Reg. No. 33,694; Vincent P. Kovalick, Reg. No. 32,867; James W. Edmondson, Reg. No. 33,871; Michael R. McGurk, Reg. No. 32,045; Joann M. Neth, Reg. No. 36,363; Carson S. Panitch, Reg. No. 33,751; Cheri M. Taylor, Reg. No. 33,216; Charles E. Van Horn, Reg. No. 40,266; and Linda A. Watler, Reg. No. 33,218; and Please address all correspondence to **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.** 1300 I Street, N.W. Washington, D.C. 20005, Telephone No. (202) 408-4000.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor <b>COLE Stewart</b>	Inventor's Signature 	Date <b>August 31 2001</b>
Residence <b>23 bis, rue Cécile Dinant, 92140 CLAMART/FRANCE</b>		Citizenship <b>FRENCH</b>
Post Office Address <b>The same as residence</b>		<b>FRX</b>

Listing of Inventors Continued on Page 2 hereof. ☒ Yes ☐ No

**FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER L.L.P.**

2-00  
3-00  
4-00  
5-00

Full Name of Second Inventor <b>GORDON Stéphen</b>	Inventor's Signature <i>Stéphen Gordon</i>	Date <b>August 31, 2001</b>
Residence <b>.48 Broadacres, Guildford, SURREY GU3 3BB / GB</b>		Citizenship <b>IRISH</b> <b>IRX</b>
Post Office Address <b>The same as residence</b>		
Full Name of Third Inventor <b>BUCHRIESER-BROSCH Roland</b>	Inventor's Signature <i>R. Brosch</i>	Date
Residence <b>11, rue de l'Amiral Mouchez, 75013 PARIS/FRANCE</b>		Citizenship <b>AUSTRIAN</b> <b>ATX</b>
Post Office Address <b>The same as residence</b>		
Full Name of Fourth Inventor <b>BILLAULT Alain</b>	Inventor's Signature <i>Alain Billaud</i>	Date <b>August 31, 2001</b>
Residence <b>46, rue du Château, 77680 ROISSY-EN-BRIE/FRANCE</b>		Citizenship <b>FRENCH</b> <b>FRX</b>
Post Office Address <b>The same as residence</b>		
Full Name of Fifth Inventor <b>GARNIER Thierry</b>	Inventor's Signature <i>Thierry Garnier</i>	Date
Residence <b>6, rue Gustave Flaubert, 95120 ERMONT/FRANCE</b>		Citizenship <b>FRENCH</b> <b>FRX</b>
Post Office Address <b>The same as residence</b>		

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER L.L.P.

## SEQUENCE LISTING

<110> COLE Stewart  
 GORDON Stéphen  
 BUCHRIESER-BROSCH Roland  
 BILLAULT Alain  
 GARNIER Thierry

<120> Deleted sequences in M. bovis BCG/M. bovis or M.  
 tuberculosis, method for detecting mycobacteria using said  
 sequences and vaccines.

<130> D18014

<150> FR 99 03 250  
 <151> 1999-03-16

<150> PCT/FR00/00637  
 <151> 2000-03-16

<160> 38

<170> PatentIn Vers. 2.0

<210> 1  
 <211> 24  
 <212> DNA  
 <213> Mycobacterium tuberculosis

<220>  
 <223> Y277-32F

<400> 1  
 gacatgtacg agagacggca tgag 24

<210> 2  
 <211> 21  
 <212> DNA  
 <213> Mycobacterium tuberculosis

<220>  
 <223> Y277-32R

<400> 2  
 aatccaacac gcagcaacca g 21

<210> 3  
 <211> 20  
 <212> DNA  
 <213> Mycobacterium tuberculosis

<220>  
 <223> plcC-B.5P

<400> 3  
 ggattcctgg actggcgcttg 20

<210> 4

"04T60" 6253660



```
<210> 9
<211> 22
<212> DNA
<213> Mycobacterium tuberculosis
```

<400> 14

agatgctcaa gccgtgcacc

<210> 15  
 <211> 22  
 <212> DNA  
 <213> Mycobacterium bovis

<220>  
 <223> TBoli2268469.F

<400> 15  
 cgcgccacaa acgtactatc tc 22

<210> 16  
 <211> 20  
 <212> DNA  
 <213> Mycobacterium bovis

<220>  
 <223> TBoli2269064.R

<400> 16  
 agtttcaccg gctgtcgttc 20

<210> 17  
 <211> 22  
 <212> DNA  
 <213> Mycobacterium bovis

<220>  
 <223> Y28-IS6110B.5'

<400> 17  
 cccacaccgc aggattggca ag 22

<210> 18  
 <211> 24  
 <212> DNA  
 <213> Mycobacterium bovis

<220>  
 <223> Y28-RHS.2

<400> 18  
 atcgagtgc tgaacgcaac cgag 24

<210> 19  
 <211> 21  
 <212> DNA  
 <213> Mycobacterium bovis BCG

<220>  
 <223> TB16.0F

<400> 19  
 gagccaacga tgatgatgac c 21

<210> 20  
 <211> 19

<212> DNA  
 <213> Mycobacterium bovis BCG

<220>  
 <223> TB16.5F

<400> 20  
 ggtcacggtc ggtgtcgtc 19

<210> 21  
 <211> 20  
 <212> DNA  
 <213> Mycobacterium bovis BCG

<220>  
 <223> TB4398.7R

<400> 21  
 cagaactgca ggggtggtac 20

<210> 22  
 <211> 21  
 <212> DNA  
 <213> Mycobacterium bovis BCG

<220>  
 <223> TB3689.5

<400> 22  
 ctagttgttc agccgcgtct t 21

<210> 23  
 <211> 19  
 <212> DNA  
 <213> Mycobacterium bovis BCG

<220>  
 <223> TB3591.0R

<400> 23  
 accggggtgt cggccagtt 19

<210> 24  
 <211> 19  
 <212> DNA  
 <213> Mycobacterium bovis BCG

<220>  
 <223> TB3689.9F

<400> 24  
 tcgcggccac cgtgcgtaa 19

<210> 25  
 <211> 20  
 <212> DNA  
 <213> Mycobacterium bovis BCG

<220>

TC4T60" E259E60

<223> TB3591.5R

<400> 25  
ggcgcctatg actgataccc

20

<210> 26

<211> 19

<212> DNA

<213> Mycobacterium bovis BCG

<220>

<223> TB3608.0F

<400> 26  
gaacaggggtc gcggagtct

19

<210> 27

<211> 20

<212> DNA

<213> Mycobacterium bovis BCG

<220>

<223> TB3672.0R

<400> 27  
tcgaggaggt cgagtcctgt

20

<210> 28

<211> 20

<212> DNA

<213> Mycobacterium bovis BCG

<220>

<223> TB3671.7R

<400> 28  
gggttcatga ggtgctaggg

20

<210> 29

<211> 22

<212> DNA

<213> Mycobacterium bovis BCG

<220>

<223> RvD5-intF

<400> 29  
gggttcacgt tcattactgt tc

22

<210> 30

<211> 20

<212> DNA

<213> Mycobacterium bovis BCG

<220>

<223> RvD5-intR

<400> 30  
cctgcgctta tctctagcgg

20

099553-0440  
"0440" 099553

<210> 31  
 <211> 19  
 <212> DNA  
 <213> Mycobacterium bovis BCG

<220>  
 <223> TB4411.0F

<400> 31  
 ccggccactc actgccttc

19

<210> 32  
 <211> 20  
 <212> DNA  
 <213> Mycobacterium bovis BCG

<220>  
 <223> TB0.3R

<400> 32  
 acggtagtgt cgtcggcttc

20

<210> 33  
 <211> 21  
 <212> DNA  
 <213> Mycobacterium bovis BCG

<220>  
 <223> TB3675.0F

<400> 33  
 ccaacaccgt caactactcg a

21

<210> 34  
 <211> 20  
 <212> DNA  
 <213> Mycobacterium bovis BCG

<220>  
 <223> TB3675.5R

<400> 34  
 atcgcagaac tccggcgaca

20

<210> 35  
 <211> 19  
 <212> DNA  
 <213> Mycobacterium bovis BCG

<220>  
 <223> TB1.2F

<400> 35  
 cgatctgac gccgacgcc

19

<210> 36  
 <211> 19  
 <212> DNA  
 <213> Mycobacterium bovis BCG

T04T60"E259E660

<220>

<223> TB1.5F

<400> 36

tccgtcagcg ctccaagcg

19

<210> 37

<211> 20

<212> DNA

<213> Mycobacterium bovis BCG

<220>

<223> TB1.8F

<400> 37

gtccccaac tgacaccct

20

<210> 38

<211> 21

<212> DNA

<213> Mycobacterium bovis BCG

<220>

<223> TB2.2R

<400> 38

aatccggaaa tcgtcagacc g

21

09440"02593660

WO 00/55362

PCT/FR00/00637

- 1 -

## SEQUENCE LISTING

&lt;110&gt; INSTITUT PASTEUR

<120> Deleted sequences in M. bovis BCG/M. bovis or M. tuberculosis, method for detecting mycobacteria using said sequences and vaccines.

&lt;130&gt; D18014

&lt;160&gt; 38

&lt;170&gt; PatentIn Vers. 2.0

&lt;210&gt; 1

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;220&gt;

&lt;223&gt; Y277-32F

&lt;400&gt; 1

gacatgtacg agagacggca tgag

24

&lt;210&gt; 2

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;220&gt;

&lt;223&gt; Y277-32R

&lt;400&gt; 2

aatccaacac gcagcaacca g

21

&lt;210&gt; 3

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;220&gt;

&lt;223&gt; plcC-B.5P

&lt;400&gt; 3

ggattccttg actggcggttg

20

&lt;210&gt; 4

&lt;211&gt; 19

&lt;212&gt; DNA

T04T60"E259E660



<213> Mycobacterium tuberculosis

<220>

<223> plcC-B.3P

<400> 4

cccacccaag aaaccgcac

19

<210> 5

<211> 20

<212> DNA

<213> Mycobacterium tuberculosis

<220>

<223> Y78-del1

<400> 5

acaaaaatcg cctcgtcgcc

20

<210> 6

<211> 24

<212> DNA

<213> Mycobacterium tuberculosis

<220>

<223> Y78-del2

<400> 6

aacctgtatt cgtcgttgct gacc

24

<210> 7

<211> 20

<212> DNA

<213> Mycobacterium tuberculosis

<220>

<223> Rv420-flank1.F

<400> 7

tggtaatcgt ggccgacaag

20

<210> 8

<211> 19

<212> DNA

<213> Mycobacterium tuberculosis

<220>

<223> RV420-flank2.R

<400> 8

tcttgcggcc caatgaatc

19

00440" E259E660

<220>  
<223> RD1.0 - 2643

<400> 13  
tcgcgaaaga ggtcatctaa ac 22

<210> 14  
<211> 20  
<212> DNA  
<213> Mycobacterium tuberculosis

<220>  
<223> DR10-267R

<400> 14  
agatgctcaa gccgtgcacc 20

<210> 15  
<211> 22  
<212> DNA  
<213> Mycobacterium bovis

<220>  
<223> TBoli2268469.F

<400> 15  
cgcgccacaa acgtactatc tc 22

<210> 16  
<211> 20  
<212> DNA  
<213> Mycobacterium bovis

<220>  
<223> TBoli2269064.R

<400> 16  
agttttcacccg gctgtcgttc 20

<210> 17  
<211> 22  
<212> DNA  
<213> Mycobacterium bovis

<220>  
<223> Y28-IS6110B.5'

<400> 17  
cccacaccgc aggattggca ag 22

<210> 18  
<211> 24  
<212> DNA  
<213> Mycobacterium bovis

04T60"E299E660

<220>  
 <223> Y28-RHS.2  
  
 <400> 18  
 atcgagtgc tgaacgcaac cgag 24  
  
 <210> 19  
 <211> 21  
 <212> DNA  
 <213> Mycobacterium bovis BCG  
  
 <220>  
 <223> TB16.0F  
  
 <400> 19  
 gagccaacga tgatgatgac c 21  
  
 <210> 20  
 <211> 19  
 <212> DNA  
 <213> Mycobacterium bovis BCG  
  
 <220>  
 <223> TB16.5F  
  
 <400> 20  
 ggtcacggtc ggtgtcgtc 19  
  
 <210> 21  
 <211> 20  
 <212> DNA  
 <213> Mycobacterium bovis BCG  
  
 <220>  
 <223> TB4398.7R  
  
 <400> 21  
 cagaactgca ggggtggtac 20  
  
 <210> 22  
 <211> 21  
 <212> DNA  
 <213> Mycobacterium bovis BCG  
  
 <220>  
 <223> TB3689.5  
  
 <400> 22  
 ctagttgttc agccgcgtct t 21  
  
 <210> 23  
 <211> 19

104160" E299E660

<212> DNA  
 <213> Mycobacterium bovis BCG  
  
 <220>  
 <223> TB3591.0R  
  
 <400> 23  
 accgggggtgt cggccagtt 19  
  
 <210> 24  
 <211> 19  
 <212> DNA  
 <213> Mycobacterium bovis BCG  
  
 <220>  
 <223> TB3689.9F  
  
 <400> 24  
 tcgcggccac cgtgcgtaa 19  
  
 <210> 25  
 <211> 20  
 <212> DNA  
 <213> Mycobacterium bovis BCG  
  
 <220>  
 <223> TB3591.5R  
  
 <400> 25  
 ggcgccctatg actgataccc 20  
  
 <210> 26  
 <211> 19  
 <212> DNA  
 <213> Mycobacterium bovis BCG  
  
 <220>  
 <223> TB3608.0F  
  
 <400> 26  
 gaacagggtc gcggagtct 19  
  
 <210> 27  
 <211> 20  
 <212> DNA  
 <213> Mycobacterium bovis BCG  
  
 <220>  
 <223> TB3672.0R  
  
 <400> 27  
 tcgaggaggt cgagtcctgt 20

0936523 091401  
T04T60 E259E600

<220>  
<223> TB0.3R

```
210> 37
<211> 20
<212> DNA
<213> Mycobacterium bovis BCG
```

<220>

<223> TB1.8F

<400> 37

gtccccaaac tgcacaccct

20

210> 38

<211> 21

<212> DNA

<213> Mycobacterium bovis BCG

<220>

<223> TB2.2R

<400> 38

aatccggaaa tcgtcagacc g

21

04160" E259E560